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Glycan Characterization and Manipulation using Phospholipid Additives for 
Capillary Electrophoresis
Stephanie A. Archer-Hartmann
 Protein glycosylation is of interest  in a number of emerging fields, and plays 
important functional roles in cellular biology. The analysis of these molecules is 
nontrivial because they exhibit great complexity in both monomer makeup and linkages 
of these monomers. As a result, a common challenge that analytical techniques face is the 
separation of linkage glycan isomers.  This dissertation is based on the research leading 
to the development of a phospholipid-capillary electrophoresis method that allows for 
highly  efficient separations and the non-covalent incorporation of enzymes and lectins for 
in-capillary interactions. Glycans were removed from glycoproteins through enzymatic 
means, then labeled with the fluorescent tag 9- aminopyrene-1,3,6-trisulfonic acid. This 
label provides charge to the otherwise neutral glycan, as well as the very  low limits of 
detection (15fM) that laser induced fluorescence detection affords. Separations 
efficiencies, based on hydrodynamic volume, were as high as 640,000 theoretical plates. 
These methods not only provide superior separations efficiencies, but  also crucial 
structural information about the glycans themselves. This method is amenable for a wide 
variety of lectins/enzymes for use, and has been conducted in a number of different 
capillary inner diameters. The method was used to probe glycans solutions taken from 
MCF7 immortalized breast cancer cells, as well as glycans from the therapeutic antibody, 
Trastuzumab. Only  microgram amounts of these proteins were need to provide the 
glycans necessary for analysis. These samples display a number of high and low 
abundance glycans that were well resolved. The identity  of these glycans were confirmed 
with the use of glycan standards as well as a number of monomer and linkage-specific 
enzymes and lectins. Multiple enzymes may be used singly, or in tandem, to 
systematically  remove glycan monomers and discern layers of information about the 
glycans in use.
DEDICATION:
This document is dedicated to my grandmothers, Marian Archer and Nettie Brannon. 
Although they were both gone before I could really know them, their legacies inspired 
me to become what I am today. 
THANK YOU:
To my husband, Jon Hartmann - for your years of support, patience, and willingness to 
pick up the phone for chinese delivery. 
To my parents, Robert and Bonnie Archer - because I know you’ll always love me, no 
matter where I go or what I do. 
To my in-laws Teresa Wayman and Paul Hartmann - for responding to my thoughts on 
whether or not to attend graduate school with a resounding “Well, why not?!”
v
ACKNOWLEDGEMENTS:
 I would like to acknowledge my advisor, Dr. Lisa Holland for all the lessons she’s 
taught me, both as a student and as an emerging professional. She pushed me to always 
go one step further and work one hour longer. Looking back on the last five years, I’m 
amazed at how much I was able to accomplish because of her guidance. Thank you Dr 
Holland, for helping me become the person I am today. 
 I would like to acknowledge and thank my committee members, Dr. Lisa A. 
Holland, Jonathan Boyd, Fred L. King, David Lederman, and Harry  Finklea for their 
invaluable support as mentors and  instructors.
 I would like to thank the West Virginia Graduate Student Fellowships in Science 
Technology Engineering and Math (STEM) program as well as the United States 
Pharmacopeia (USP)’s Fellowship  program.  Not only did these programs provide the 
funding for me to focus my full attention on research, but they provided a number of 
opportunities for me to further develop as a researcher and professional.
 
 I would like to acknowledge my lab mates (past and present) : Dr Theron Pappas, 
Dr Christian White, Dr Liliya Bykova, Dr. Ruijuan Luo, Ted Langan, Xingwei Wu, 
Brandon Durney, Vincent Nyakubaya, Tyler Davis, and Hanyu Fan. Thank you for the 
assistance, support, teamwork, dancing hamsters, and flying Peeps. You have been a 
joyous part of my life, and I wish you all nothing but the best in years to come.
vi
TABLE OF CONTENTS
----------------------------------------------------------------LIST OF FIGURES xii
-----------------------------------------------------------------LIST OF TABLES xiv
-----------------------------------LIST OF SYMBOLS /NOMENCLATURE xv
Chapter 1
Introduction to Capillary Electrophoresis, Phospholipid Materials, and 
------------------------------------------------------------------------------------Glycans 1
---------------------------------------------------------------------1.0 Introduction 2
---------------------------------1.1.1 Theory of Capillary Electrophoresis 3
----------------------1.1.2 Instrumentation of Capillary Electrophoresis 4
---------------1.1.3 Electrophoretic Mobility and Electroosmotic Flow 6
-----------------------------------------1.1.4 Resolution of Analytes in CE 8
----------------------------------------------------1.2 Phospholipid Separations 10
---------------------------------------------1.2.1 Phospholipid Separations 12
-----------------------------------------------------1.3 Oligosaccharide analysis 13
------------------------------------------------------------------1.3.1 Glycans 14
----------------------1.3.2 Derivatization of Glycans for CE separations 17
--------------------------------------------------------------------1.2 Bibliography 19
Chapter 2
Development of Phospholipid Assisted CE for Efficient Glycan 
-------------------------------------------------------------------------------Separations 24
---------------------------------------------------------------------2.1 Introduction 25
-----------------------------------------------------------2.1.1 Phospholipids 25
2.1.2 Effects of Phospholipid Composition on Separations 
--------------------------------------------------------------------Performance 27
vii
-----------2.1.3 Utilization of Bicelle Coatings and Separations Media 27
--------------------2.1.4 Effects of Q-value, Hydration and Temperature 28
----------------------------------------------------2.1.5 Sample Introduction 29
-------------------------------------------------------------------2.2 Experimental 30
----------------------------------------------2.2.1 Chemicals and Materials 30
------------------------------------2.2.3 Glycan Labeling and Preparation 30
----------------------------------------------2.2.4 Phospholipid Preparation 32
---------------------------------------------2.2.5 Capillary Electrophoresis 32
--------------------------------------------------------2.3 Results and Discussion 34
----------------------------------2.3.1 Effects of Capillary Inner Diameter 34
----------------------------------------------2.3.2 Optimization of Injection 34
--------------------------2.3.3 Effects of Capillary Length on Efficiency 38
-------------------2.3.4 Effects of Electric Field Strength on Efficiency 39
-----------------------------------------------------2.3.5 Limits of Detection 42
----------------------------------------------------------------------2.4 Conclusions 42
--------------------------------------------------------------------2.5 Bibliography 43
Chapter 3
Optimization of In-Capillary Interactions of Glycans to Lectins and 
-----------------------------------------------------------------------------------Enzymes 45
---------------------------------------------------------------------3.1 Introduction 46
-------------------------------------------------------------------3.1.1 Lectins 47
-----------------------------------------------------3.1.2 Mass Spectrometry 48
---------------------------------------------3.1.3 Exoglycosidase Enzymes 49
-------------------------------------------------------------------3.2 Experimental 50
viii
----------------------------------------------3.2.1 Chemicals and Materials: 50
--------------3.2.2 Preparation and Derivatization of Glycan Standards 51
-------------------------------3.2.3 Preparation of Phospholipid Additive 52
---------------------------------------------3.2.4 Capillary Electrophoresis 53
---------------------------------------------------3.2.5 Enzymatic Reactions 54
--------------------------------------------------------3.3 Results and Discussion 54
----------------3.3.1 Methods of Glycan Identification using Standards 55
3.3.2 Utilization of Lectins and Enzymes for Glycan 
---------------------------------------------------------------Characterization 57
----------------------3.3.3 In-Capillary Reactions of Glycans to Lectins 58
---------------------------------------------------------3.3.4 Concanavalin A 59
--------------------------3.3.5 Use of Enzymes for In-Capillary Analysis 62
------------------------------------------------------------3.3.6 Mannosidase 64
-----------------------------------------------------------3.3. 7 Galactosidase 67
----------------------------------------------------------3.3.8 Neuraminidase 69
--------------------------------------------3.3.9 Multiple enzyme Methods 70
--------------------3.3.11 In-Capillary Sequential Enzymatic Reactions: 74
----------------------------------------------------------------------3.4 Conclusions 77
--------------------------------------------------------------------3.5 Bibliography 78
Chapter 4
---Applications of Method to Biological Samples: MCF7 and Trastuzumab 81
--------------------------------------------------------------------4.1 Introduction: 82
----------------------4.1.1 Glycomics and Clinical Biomarker Research 82
-------------------------------------------------------------------4.1.2 MCF-7 83
ix
-----------------------------4.1.3 Therapeutical Biologics and Antibodies 84
--------------4.1.4 Antibody Structure and the Effects of glycosylation 84
----------------------------------------------4.1.5 Trastuzumab (Herceptin) 87
----------------------------4.1.6 Quality by Testing vs Quality by Design 89
-------------------------------------------------------------------4.2 Experimental 90
----------------------------------------------4.2.1 Chemicals and Materials: 90
---------------------4.2.2 Culture of MCF7 Cells and Protein Isolations 91
4.2.3 Preparation and Derivatization of Glycans from MCF7 and 
-------------------------------------------------------------------Trastazumab 91
-------------------------------4.2.4 Preparation of Phospholipid Additive 93
---------------------------------------------4.2.5 Capillary Electrophoresis 93
--------------------------------------------------------4.3 Results and Discussion 94
4.3.1 Separation of Glycans from MCF7 Cells and Identification with 
--------------------------------------------------------------Glycan Standards 96
----------------------------4.3.2 Analysis of MCF7 with Concanavalin A 96
--------------4.3.3 Analysis of MCF7 with galactosidase, mannosidase 98
------------4.3.4 Identification of the major glycans from Trastuzumab 100
--------------------------4.3.5 Separations of glycans from Trastuzumab 100
---------4.3.6 Characterization of sialyated glycans from Trastuzumab 103
-----------------------4.3.7 Analysis with multiple in-capillary enzymes 105
4.3.8 Use of multiple enzyme plugs to Characterize Major Glycans from 
-------------------------------------------------------------------Trastuzumab 106
4.3.9 Benefits of Using In-Capillary Analysis for Multiple Enzyme 
--------------------------------------------------------------------------Studies 110
----------------------------------------------------------------------4.4 Conclusions 113
-------------------------------------------------------------4.5 Future Directions: 114
x
--------------------------------------------------------------------4.6 Bibliography 115
-----------------------------------------------------------CURRICULUM VITAE 121
xi
LIST OF FIGURES
Chapter 1 Figures
Figure 1-1: ------------- Schematic of CE instrument and Electropherogram  5
Figure 1-2: --------------------------------------------- Separation of Ions in CE  7
Figure 1-3: -----------Supramolecular assemblies of DMPC/DHPC bicelles 11
Figure 1-4: ---------------------- Glycan monomers typical to N-type glycans 15
Figure 1-5: ------------- High Mannose, Complex, and Hybrid type glycans 16
Figure 1-6: ----------------------------------------------- APTS labeling strategy 18
Chapter 2 Figures
Figure 2-1 ------------------------------------: Structures of DMPC and DHPC 26
Figure 2-2 --------------------: Plot of Plate Height vs Electric Field Strength 41
Chapter 3 Figures
Figure 3-1: -----------------------------Electropherogram of glycan standards 56
Figure 3-2: ----------------------------------- Schematic of Lectin plugs for CE 59
Figure 3-3: ------Electropherogram of Con-A modified Glycan separations 61
Figure 3-4: -------------------------------- Schematic of Enzyme plugs for CE 63
Figure 3-5: Schematic of Multiple Incubation times with Enzyme modified 
--------------------------------------------------------------------------------------CE 64
Figure 3-6 -----------: Electropherogram of Mannosidase modified glycans  66
Figure 3-7: ----------- Electropherogram of Galactosidase modified glycans 68
xii
Figure 3-8: --------------------- AIV glycan structure with enzymatic targets. 71
Figure 3-9: --------- Bench-top multi-enzyme analysis of glycan from AGP 73
Figure 3-10: ----------------------- On-line multi-enzyme analysis of glycans 76
Chapter 4 Figures
Figure 4-1: -------------------------------- Structure of IgG and glycosylation  87
Figure 4-2: ------------------------- Electropherogram of glycans from MCF7 98
Figure 4-3: -------------Enhanced electropherogram of glycans from MCF7 99
Figure 4-4: ----------------------- Major glycan structures from Trastuzumab 100
Figure 4-5: ----------------- Electropherogram of glycans from Trastuzumab 102
Figure 4-6: Electropherogram of Neuraminidase modified glycans from 
--------------------------------------------------------------------------Trastuzumab 104
Figure 4-7: --------------------------- Schematic of Multiple Enzymes for CE 106
Figure 4-8: Schematic of multiple enzyme analysis and electropherogram of 
--------------------------------------------------------------------------Trastuzumab 108
Figure 4-9: Electropherogram of multi-enzyme modified glycans from 
--------------------------------------------------------------------------Trastuzumab 109
Figure 4-10: Comparison of bench top methods for multiple enzyme 
--------------------------------------------------------------------------------analysis 112
xiii
LIST OF TABLES
Chapter 2
Table 2-1 -----------------------------------------: Comparison of Pre-Plug Size 35
Table 2-2 -----------------------------------: Comparison of two Pre-plug sizes 35
Table 2-3 -------------------------------------------------: Effect of post plug size 36
Table 2-4 ------------------: Effect of Injection Size on Area Reproducibility 37
Table 2-5 -------------: Effect of Injection Size on Precision and Plate Count 37
Table 2-6 ------------: Effect of Length on Separation Efficiency (branched) 39
Table 2-7 ----------------: Effect of Length on Separation Efficiency (linear) 39
xiv
LIST OF SYMBOLS /NOMENCLATURE
1. AGP - α-acid glycoprotein
2. ANTS - 8-aminonaphthalene-1,3,6-trisulfonic acid
3. APTS - 1-aminopyrene-3,6,8-trisulfonic acid
4. CBQCA - 3- (4-carboxybenzoyl)-2-quinolinecarboxaldehyde
5. CE - capillary electrophoresis
6. CEC - capillary electrochromatography
7. CGE - capillary gel electrophoresis
8. CEIF - capillary isoelectric focusing
9. CZE - capillary zone electrophoresis
10.i.d.  - inner diameter
11.DHPC - 1,2-dihexanoyl-sn-glycero-3-phosphocholine
12.DMPC -1,2-dimyristoyl-sn-glycero-3-phosphocholine
13.ek - electrokinetic
14.EOF - electroosmotic flow
15. ESI - electrospray ionization
16.HPLC - high performance liquid chromatography
17.L - length of the capillary
18.Leff - effective length of the capillary
19.LIF - laser induced fluorescence
20.MEKC - micellar electrokinetic chromatography
21.MS - mass spectrometry
xv
22. MALDI - Matrix-assisted laser desorption/ionization
23.η - viscosity
24.o.d. - outer diameter
25. q - charge
26. q value - ratio of [DMPC]/[DHPC]
27.UV - ultraviolet
xvi
xvii
Chapter 1
 
Introduction to Capillary Electrophoresis, Phospholipid 
Materials, and Glycans
1
1.0 Introduction
 Capillary  electrophoresis (CE) is a rapid separations method that provides high 
resolution and separation efficiencies. CE is well suited for the separations of biological 
molecules because as a microscale technique it  uses very  low volumes of analyte per 
analysis. With optical methods such as laser induced fluorescence (LIF), low limits of 
detection may  be achieved. CE separations have been used in the analysis of glycans 
[1-4]. Recently phospholipid additives were incorporated into CE separations for the 
separation of glycans [5]. This research explored the effects of temperature, phospholipid 
content, and composition on the performance of the separation. The use of phospholipid 
media is attractive for CE separations because it separates glycans efficiently and the 
material is easily incorporated into separation capillaries. 
 The research covered in this body of work further investigates the use of 
phospholipid additives in CE for the analysis of glycans. This research documents the 
expanded and practical applications of this separations technique. Chapter 1 discusses the 
fundamentals of capillary electrophoresis, phospholipid materials, and glycans. Previous 
work by Luo et al demonstrated the first  use of phospholipids in capillary electrophoresis 
for the analysis of glycans. Chapter 2 covers the expanded optimization of glycan 
separations since that first publication. It covers the effects of modified injection protocol 
and separation conditions for on-column detection. Chapter 3 covers the expansion of the 
existing separation methodology  to include glycan-specific selectors such as enzymes and 
lectins, for on-capillary  analysis of glycans.  Finally, these methods are applied to the real 
2
world samples of glycans taken from MCF7 immortalized breast cancer cells and the 
therapeutic antibody Trastuzumab in Chapter 4. This work covers research that  has been 
published in: 
Archer-Hartmann, S.A., Crihfield, C.L., Holland, L.A., On-Line Enzymatic Sequencing of 
Glycans from Trastuzumab by Phospholipid Capillary Electrophoresis, Electrophoresis, 
2011. accepted
Archer-Hartmann, S.A., Sargent, L.M., Lowry, D.T., Holland, L.A., Microscale 
Exoglycosidases Processing and Lectin Capture of Glycans with Phospholipid Assisted 
Capillary Electrophoresis Separations, Analytical Chemistry, 2011. 83: p. 2740-2747
Luo, R., Archer-Hartmann, S.A., Holland, L.A., Transformable Capillary Electrophoresis 
for Oligosaccharide Separations Using Phospholipid Additives, Analytical Chemistry, 
2010. 82: p. 1228-1233
1.1.1 Theory of Capillary Electrophoresis
 To better understand the separations processes that make the developed methods 
described in subsequent chapters possible, this section will cover the basics of capillary 
electrophoresis (CE). CE was first reported in the 1980s by the Jorgenson group  [6,7]. CE 
is characterized as providing rapid, efficient separations of molecules based on their 
charge-to-size ratios. Applications of CE methodologies include profiling a number of 
analytes in bioanalysis such small molecule pharmaceuticals, analysis of peptides and 
3
proteins, oligonucleotides, and DNA [8]. A number of methods exist in the capillary 
electrophoresis family  including capillary isotachophoresis (CITP), capillary isoelectric 
focusing (CIEF), micellar electrokinetic capillary  chromatography (MEKC), and 
capillary gel electrophoresis (CGE). Additionally methods for capillary  electrophoresis 
can be easily adapted to microfluidic methods for the development of portable and 
disposable means of analysis. 
1.1.2 Instrumentation of Capillary Electrophoresis
 At its most  fundamental, CE instrumentation is comprised of three general parts: a 
narrow bore (~10 to 100µm i.d.) capillary made from fused silica that is filled with and 
held between two buffer vials, a power supply to provide voltage, and a method of 
detection. The fused silica capillary is narrow bore and is often coated in polyimide to 
prevent breakage. The capillary can be cut to a specified length with a ceramic cutter. To 
prepare a window for optical modes of detection, a propane or butane torch is frequently 
used to remove a small segment of the the polyimide coating. The placement of anode -
inlet  and cathode-outlet to the capillary for separation is known as normal polarity. 
Switching the the cathode and anode for separation (cathode-inlet and anode-outlet) is 
known as a reverse polarity separation. Commercial instrumentation often incorporates 
methods of automated sample handling, as well as methods of temperature control for the 
samples and thermostatting of the capillary.  Commercial CE instruments are often 
available with a number of pre-equipped detection modes, such as UV-absorbance 
4
detection or laser induced fluorescence (LIF). Commercial CE instruments also are 
amenable for on-line coupling to electrospray ionization-mass spectrometry. 
 Following the application of voltage within the capillary, analytes are separated 
and eluted, based on their charge-to-size ratio. Figure 1-1 provides the basic schematic 
for this instrument, as well as a basic electropherogram readout. 
+ -
to detector
HVPS
buffer (or sample) vials
time
signal
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Figure 1-1: Schematic of CE instrument and Electropherogram: Figure 1 shows 
the basic schematic of a capillary electrophoresis instrument including a fused silica 
capillary held between two buffer vials attached to a high voltage power supply. Also 
shown is a representation of an electropherogram showing the separation of three 
analytes. 
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1.1.3 Electrophoretic Mobility and Electroosmotic Flow
 When a voltage is applied to the capillary, the analytes within it move as a result 
of their electrophoretic mobility. This mobility  is direction dependent, negatively charged 
species will migrate toward the anode, while positively charged species will migrate 
toward the cathode. The velocity of this migration is dependent on the analytes’ charge-
to-size ratio and can be further described as 
µ = q / (6πηr)              (1-1)
where q is the net charge of the analyte, η s the viscosity  of the separations media or 
buffer, and r is the hydrodynamic radius of the analyte. During separation, the various 
analytes within the capillary will separate based on their individual electrophoretic 
mobilities as discrete bands or zones. This separation method is known as capillary zone 
electrophoresis. During separation, molecules that are net positive, net negative, or 
neutral all migrate to the detection window.  This indicates that  there is secondary  force at 
work within the separations capillary. This force, known as electroosmotic flow, occurs as 
a result of the charged nature of the fused silica capillary inner wall. The silica surface 
imparts charge in the form of negative silanol groups in a buffer solution. This charge 
attracts positive ions from the buffer solution that forms two discrete layers, known as an 
electronic double layer. The first, known as the Stern layer, is a thin layer of positively 
charged ions that lays static against the silanol groups. The second, less dense layer of 
positive ions is known as the Outer Helmoltz plane (OHP). Under an applied voltage, this 
diffuse layer will migrate toward the cathode, pulling waters of hydration with it. Due to 
the small inner diameters inherent to CE, this action results in a bulk flow through the 
6
capillary. Electroosmotic flow, also known as EOF, provides a nonmechanical method of 
liquid flow through the capillary, and boasts a plug-like fluid flow profile that results in 
less band broadening than that  of hydrodynamic flow. However, EOF is frequently a 
challenge to reproducibly control. EOF flow rates that  are too small result in long 
migration times and increased time-dependent band broadening for neutral and negative 
species. EOF flow rates that are too fast  result  in analytes reaching the detector before 
they  have adequate time to separate. The magnitude of EOF is dependent on both the pH, 
and ionic strength of the separations buffer. It is common practice in capillary  zone 
electrophoresis to include a known neutral analyte standard as a means to monitor the 
electroosmotic flow. A simplified schematic of how electrophoretic mobility  and 
electroosmotic result in the separation of analytes is shown in Figure 1-2. 
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Figure 1-2 shows the migration of  ions in capillary electrophoresis. An electronic 
double layer forms at the wall of  the capillary, which is the impetus for a bulk 
electroosmotic flow. Analytes separate due to their individual electrophoretic mobilities, 
which are due to the charge and size of the analyte. 
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1.1.4 Resolution of Analytes in CE 
 The simplest  way to characterize the separation of two bands of analyte is to 
divide the difference in the migration distance (x) by the average peak width (w) , as seen 
in:
 R = 2 (x2-x1)/(w1+w2)         (1-2)
In the case of capillary separations, x would be determined by the electrophoretic 
mobility  of the analyte, while w would be determined by the amount of band broadening 
during separation.  If we redefine resolution in terms of a Gaussian distribution
R = ∆xi/4σ   (1-3)
The two peaks touch at the baseline when ∆x = 4σ and R=1. We can further use variance 
(σ) for the definition of theoretical plate count where
N = L2/σ2     (1-4)
and the height equivalent of a theoretical plate, or HETP is
HETP = L/N = σ2tot/L  (1-5)
8
These equations describe the efficiency of the separation, is a description of the analyte 
peak shape, and is a useful concept to relate factors of the analytical separation method. It 
is important to note that the total variance of the separation is due to a number of 
dispersive factors and can be rewritten as:
σ2tot = σ2diff + σ2T + σ2int + σ2wall + σ2other   (1-6)
 These sources of variance include variances due to analyte diffusion (σ2diff) within 
the capillary, variance due to temperature (σ2T) due to heating as a result of current 
passing through the capillary, variances due to the injection of sample into the capillary 
(σ2int), variances due to interactions of the analyte with the capillary wall (σ2wall) and 
other variances (σ2other). These other variances may include specific or nonspecific 
interactions of the analyte, such as interactions of the glycans to lectins or enzymes. This 
is further discussed in Chapters 3 and 4.  Variances due to the injection of sample into the 
capillary will be discussed in Chapter 2. 
 Increasing the migration distance the analytes must travel has been shown to 
increase analyte resolution. This can be accomplished by increasing the effective 
capillary length [9,10]. This effect  is determined from Giddings [11] which expresses the 
resolution as:
Rs = ( N1/2 / 4)(∆υ/ῡ)          (1-7)
9
where N is the number of theoretical plates, and (∆υ/ῡ) is the relative velocity difference 
between two analytes. This states that resolution can be related to theoretical plate count. 
Jorgenson and Lukas [6] further describe this relationship  by stating that, if band 
broadening in CZE can be attributed only  to molecular diffusion longitudinally, the plate 
count can be given as:
N = l2/2Dt                           (1-8)
where D is the diffusion coefficient of the analyte, l is the effective length of the 
separation, and t is the migration time of the analyte through the effective length. This 
means that  a method of improving separation efficiency  is to increase the length of the 
separation. This effect is further explored in Chapter 2. 
1.2 Phospholipid Separations
 Because the electrophoretic mobility of an analyte is proportional to the viscosity 
of the separations media, higher viscosities will result in longer separation times and 
better resolved analytes. Solutions of phospholipids known as bilayered micelles, or 
bicelles, are known to have changeable viscosities that are dependent on temperature. 
These phospholipids can be easily introduced into the capillary and provide superior 
resolution and separation efficiencies in CE separations.  The phospholipid preparations 
10
of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-dihexanoyl-sn-
glycero-3-phosphocholine (DHPC) used as a separations media in this research undergo 
various morphologies, and thus viscosities. These morphologies are bilayered micelles 
(bicelles), ribbon-like micelles, and transient interconnected bilayer networks shown in 
Figure 1-3 [12-14].
A C
D
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DHPC
B
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Figure 1-3 shows the phospholipids of study, and their supramolecular morphologies. 
Figure 3-A shows the two phosphocholine phospholipids used for these studies, short 
chained DHPC and long chained DMPC. Also shown are the morphologies of these 
lipid preparations: free floating bicelle discs, long chained ribbons, and entangled 
ribbons, Figure 3-B, 3-C, and 3-D respectively. Figure adapted from [12].
 
 Bicelles are disk-like structures with a circular center of bilayered DMPC capped 
with a rim of DHPC (Figure 1-3-B). The radius of this disc is dependent on temperature, 
hydration, and q value, or the concentration ratio of DMPC to DHPC. This is the primary 
11
structure of bicelle preparations at room temperature. At higher temperatures (~24 ℃) the 
morphology  of the bicelle transitions from disc bicelles to a ribbon-like micelle (Figure 
1-3-C) [12]. This morphology results in an substantial increase in viscosity. As the 
temperature increases these ribbons become more entangled, and result in a further 
increase in viscosity  (Figure 1-3-D). This phospholipid material makes an excellent 
additive for capillary electrophoresis, as it can be easily introduced into the capillary at 
low temperatures unlike the highly viscous linear polymer additives used in capillary gel 
electrophoresis. 
1.2.1 Phospholipid Separations
 Phospholipids have been used in a number of capillary-based separations 
techniques. Phospholipid preparations have been used as a coating in CE to suppress the 
electroosmotic flow and to prevent nonspecific adsorption to the capillary walls [15-18]. 
They  have also been polymerized to immobilize proteins in capillaries and microfluidics 
for affinity targeting [19,20] , and have been used as a pseudo-stationary phase [21,22].
 It is important to note that separations of glycans in phospholipid media are not 
due to sieving. Sieving is a common separation scheme for biopolymers such as the case 
of separation DNA molecules based on size [23]. Plotting the logarithm of velocity vs the 
logarithm of molecular mass of homologous series (Ferguson plot) and comparison the 
resulting slope provides information the mode of separation. Separation of glycans (linear 
12
or branched) were found to have same slope below and above the entanglement 
thresholds for the gel in use, indicating that glycans separated by  capillary  gel 
electrophoresis separate strictly on differences in charge to size ratio [24]. The same 
experiment was accomplished with glycan separations in phospholipid media. The data 
fit for glycans separated in phospholipid media was linear (R2 = 0.998) with slopes of 
(-0.620) that  were the same above and below the entanglement threshold of the polymer 
[5]. This indicates that glycans in phospholipids also are separated based on their 
hydrodynamic volumes through a viscous media, and not  through a mechanism of 
sieving. 
1.3 Oligosaccharide analysis
 
 The analysis of carbohydrates provide unique challenges to separations scientists. 
Glycans affect numerous crucial biological processes and are the molecule of interest in 
many biochemical studies. While oligosaccharides tend to be similar in overall chemical 
composition, they display highly  complex structures as a result of variable linkage, 
position, and type.  Therefore glycans make excellent test molecules to assay the 
efficiency and resolution of a separations technique such as capillary electrophoresis. 
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1.3.1 Glycans
 Carbohydrates are among the most abundant of biological molecules, and affect 
numerous aspects of cellular development and biochemistry. Cellular glycosylation is 
essential for cell-to-cell communication and internal cellular communication. Glycans 
affect the folding of proteins as a post-translational modification, as well as the solubility, 
antigenicity, and eventual clearance of the protein from the body [25]. Glycans derived 
from glycoproteins are either N- (asparagine), or O- (serine/threonine) linked to the 
polypeptide sequence of the protein.  The focus of this body of work is on N-liked 
glycans. Oligosaccharides are comprised of multiple glycan monomers, and monomers 
common to N-linked glycosylation include N-acetylglucosamine (GlcNAc), galactose 
(Gal), glucose (Glc), mannose (man), fucose (Fuc), and N-acetylneuraminic acid 
(NeuAc) (structures shown in Figure 1-4). 
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Figure 1-4 shows glycan monomers typical to N-type glycosylation. 
 N-glycans all contain a di-GlcNAc, tri-Man core that is attached to the protein. 
Oligosaccharides can be connected through variable monomer linkage positions and 
types (α or β) but fall into common overall structure types (Figure 1-5). The overall 
structures of N-linked glycans can be broken into 3 broad types.  These include complex 
type glycans, high mannose glycans, and hybrid glycans that  combine characteristics of 
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the two. These structures can be further modified through bisecting GlcNAc monomers, 
and the addition of fucose.
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Tuesday, October 11, 2011Figure 1-5 shows examples of high mannose, complex, and hybrid type glycans. Also 
shown is a key describing the various glycan monomers and linkages described in the 
text.
 Both simple and complex carbohydrates tend to be similar in structures, 
consisting primarily of polyhydroxylated hydrocarbons that are usually very polar and 
nonvolatile. While carbohydrates display highly  similar structures in chemical structure, 
the overall complexity can be extensive. This is demonstrated in the comparison of of 
glycan linkages to amino acid linkages. For example, while 2 identical amino acids link 
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into a single dipeptide, 2 identical glucose molecules can form 11 different disacchardies. 
Four different hexopyranoses can produce more than 36,000 different tetrasaccharides 
[26]. Issues of linkage, position, and type result in great complexity of the final glycan 
structure. 
1.3.2 Derivatization of Glycans for CE separations
 
 A challenge to analyze oligosaccharides is that they are not easily detected 
through optical methods. Carbohydrates are not naturally chromophoric or fluorophoric 
and thus are not amenable to detection with UV-absorbance or laser-induced 
fluorescence. Additionally, glycans, which naturally contain charge only through in 
inclusion of sialic acid, are neutral. Labeling the glycan with a fluorescent tag often 
serves to provide charge to the molecule, and thus a method of electrophoretic migration 
through the capillary. A variety of derivatization reagents have been reported by the 
fluorescence detection of mono- and oligosaccharides in CE, and include labels such as 
3- (4-carboxybenzoyl)-2-quinolinecarboxaldehyde (CBQCA) [27] , 8-
aminonaphthalene-1,3,6-trisulfonic acid (ANTS) [28], and 1-aminopyrene-3,6,8-
trisulfonic acid (APTS) [29]. The use of APTS for the derivatization of glycans has been 
well documented and is the label used for this research.
 The labeling strategy  for APTS is shown in Figure 1-6. The amine group from 
APTS attaches to the anomeric carbon of the sugar to form a reversible Schiff base. This 
bond attaches through reductive amination, and is further reduced to a stable bond with 
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the incorporation of sodium cyanoborohydride. The APTS provides three additional 
negative charges to the glycan molecule. The labeling of APTS occurs in a 1:1 fashion 
with the sugar, proving a constant application of charge and label, and allowing for the 
development of quantitative analysis and for the separation of the glycan based on 
charge. 
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Monday, October 10, 2011Figure 1-6 displays the reaction scheme for the derivatization of carbohydrates with 
APTS.  
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Chapter 2
 
Development of Phospholipid Assisted CE for Efficient 
Glycan Separations 
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2.1 Introduction
 The separations of glycans using phospholipid additives in capillary 
electrophoresis was first reported by Luo et al in 2010 [1]. In this application, 
phospholipids served to suppress the electroosmotic flow and acted as a viscous 
separation media to improve analyte resolution and efficiency. This chapter covers the 
advancement of phospholipid separations in terms of injection optimization, capillary 
inner diameter, capillary length, and field strength. 
2.1.1 Phospholipids
 Phospholipids have been utilized to enhance chemical separations for studies of 
membrane affinity [2], lipophilicity [3], and liposome interaction [4], and as a 
pseudostationary phase to separation proteins [5]. Phospholipids are excellent coatings 
for capillary electrophoresis, as they are naturally biocompatable, and form semi-
permanent coatings that do not require covalent  modification of the capillary, nor the 
presence of the phospholipid in the running buffer. The phospholipids used for the 
separation of glycans consist  of the long chain phosphocholine 1,2-dimyristoyl-sn-
glycero-3-phosphocholine (DMPC) and 1,2-dihexanoyl-sn-glycero-3-phosphocholine 
(DHPC) shown in Figure 2-1. 
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1,2-dimyristoyl-sn-glycero-3-phosphocholine
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Figure 2-1 displays the chemical structures of DMPC and DHPC, the two 
phospholipids used for this body of work. 
 Aqueous preparations of these two phospholipids are described in terms of molar 
ratios of [DMPC]/[DHPC], or the q value of the solution. Aqueous phospholipid 
preparations comprised of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 
1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC) display atypical temperature-
dependent viscosity. At temperatures below the gel phase transition, the viscosity of an 
aqueous phospholipid preparation is similar to that of water. Above the gel phase 
transition, the viscosity  increases dramatically to a maximum at ∼29 °C. [6] The 
temperature-induced change in viscosity of aqueous phospholipid preparations is a 
function of the q-value as well as the percent hydration. The viscosity can increase with 
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temperature as much as 370-fold for q = 2.5-10% phospholipid preparations and even 
more so when comparing preparations of different q-values [6]. This transition has 
practical use for capillary  electrophoresis separations, as they  are easily  introduced into 
the capillary  at low temperatures as an additive for chemical separations.  
2.1.2 Effects of Phospholipid Composition on Separations Performance
 To appropriately utilize phopsholipid bicelles for the separations of small 
molecules such as glycans, a number of parameters were characterized by Luo et al [1]. 
Because the morphology  of the phospholipid affects its overall properties as a separations 
media,  the effects of lipid content, composition, and temperature on the the separation 
were determined. The previous research in this field provided a starting point  to this body 
of research.
2.1.3 Utilization of Bicelle Coatings and Separations Media
 The method of sample introduction for phospholipid-mediated capillary 
electrophoresis separations must account for a significant temperature dependent change 
in viscosity  of the media. Therefore, the filling of the capillary, and other hydrodynamic 
injections are performed for phospholipid preparations of different viscosity  by injecting 
samples at temperatures below the gel-phase transition at which all phospholipid 
preparations display similar low viscosity. Following the injection, the capillary 
temperature is increased to a specified value and the separation proceeds. This protocol 
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can increase the total analysis time by as much as 5 min but is necessary to compare 
open-tubular separations with phospholipid-mediated separations.
2.1.4 Effects of Q-value, Hydration and Temperature
 Previous research compared three different ratios of [DMPC]/[DHPC], or q-
values. Q-values of q = 1.5, 2.0, and 2.5 were compared at equivalent percent hydration 
(5%). Separations of branched glycans were conducted using these three solutions at 
various temperatures ranging from 21 to 35 ℃. The migration reproducibility varied with 
the q value, with q values of 2.5 providing the best reproducibility.  While there was no 
discernible trend in the theoretical plate count or resolution of glycans with these three 
5%, phospholipid preparations, q = 2.5 phospholipid preparations were used to provide 
the reproducibilities needed for more precise analysis. 
 Q = 2.5 phospholipids at 5, 10, and 15% preparations were also compared at 
various temperatures (21 to 35℃) in terms of separation efficiency and resolution. Q 2.5, 
10% preparations provided overall better separations than the other two percent 
hydrations. A separation of the branched glycans taken from bovine asialofetuin showed 
that, for a 40.2 cm capillary (30.2 cm effective length) with a 50 µm i.d, theoretical plate 
counts as high as 240,000 could be obtained. These maximum efficiencies, and the 
maximum resolutions were obtained at 25 ℃. Therefore this report utilized phospholipid 
additives that were q = 2.5, 5% hydration and were used for separations at 25 ℃, and 
were also used for the studies in this body of work. 
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2.1.5 Sample Introduction
 The method of sample introduction a the capillary must account for the significant 
change in viscosity  following change in temperature to the phospholipid separations 
media. This viscosity can result in inconsistent injections if a suitable protocol for the 
electrokinetic introduction of sample into the capillary is not used. Luo et al first  reported 
the use of a small aqueous plug of buffer into the phospholipid before and after the 
electrokinetic injection of the glycan [1]. Electrokinetic sample introduction is also 
frequently employed in capillary  gel electrophoresis, where a small aqueous plug is 
hydrodynamically injected into the capillary before electrokinetically injecting the 
analyte. Inclusion of this pre-plug was shown to improve sample introduction [1,7]. A 
small plug of buffer following the electrokinetic injection was also shown to reduce peak 
tailing [8] and thus was also incorporated .The protocol utilizes an aqueous pre-plug of 
MOPS into the phospholipid material before and after the analyte is electrokinetically 
injected. These pre and post  plugs improve the reproducibility  of peak area and greatly 
reduces peak asymmetry. 
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2.2 Experimental 
2.2.1 Chemicals and Materials
Reagents were obtained from a variety  of manufacturers. Sigma Aldrich (St. Louis, MO, 
USA) was the source for asialofetuin from fetal calf serum, 3-(N-morpholino)-
propanesulfonic acid (MOPS), calcium chloride dihydrate, maltooligosaccharide 
standards, sodium chloride, and sodium hydroxide. Methanol and α1-acid glycoprotein 
(AGP) were purchased from EMD Biosciences (La Jolla, CA). Ethanol was obtained 
from AAPER Alcohol (Shelbyville, KY). 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(DMPC) and 1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC) were obtained from 
Avanti Polar Lipids (Alabaster, AL). 1-aminopyrene-3,6,8-trisulfonic acid (APTS) was 
purchased from Biotium (Hayward, CA). Sodium cyanoborohydride (NaCNBH3) was 
acquired from Strem Chemicals (Newburyport, MA). Triethylamine, acetonitrile, and 
citric acid were acquired from Fisher Scientific (Pittsburgh, PA).  An Elga Purelab ultra 
water system (Lowell, MA) was used to provide deionized water.
2.2.3 Glycan Labeling and Preparation
Glycans derived from glycoproteins (Rnase B, asialofetuin, and α-acid glycoprotein) 
were prepared as follows. Glycans were removed from protein sources using a PNGase F 
kit using protocol based on the kit from the manufacturer. Briefly the protein is denatured 
using a solution containing sodium dodecyl sulfate (SDS), dithiothreitol (DTT) and 
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heating at 95 ℃ for 10 minutes. The nonionic surfactant NP-40 is then added to the 
solution to prevent the DTT from denaturing the enzyme PNGase F, which immediately 
added afterward. This reaction was incubated at 37 ℃ overnight, rather than the 2 hours 
suggested by the protocol. The next day, a 3X volume of ice-cold ethanol was added to 
precipitate the protein. The solution was centrifuged at 4 ℃ at 10 000 rpm for 10 
minutes. The liquid fraction containing cleaved glycans was dried using a Savant 
SpeedVac concentrator (ThermoScientific, Waltham, MA). The dried glycans , or dried 
glycan standards were reconstituted in 1µL  of a 0.2 M  solution of APTS dissolved in 1.2 
M citric acid, along with 1µL of 1 M  NaCNBH3 in deionized water. The solution was 
thoroughly  mixed before being incubated overnight at 37 ℃. The reaction was stopped 
with the addition of 100 µL of deionized water. If needed, the sialic acid was removed by 
adjusting the pH of the glycan solution to 6 with sodium hydroxide then incubating it 
overnight with neuraminidase. If necessary, a 10 kDa molecular weight cut off filter 
(Sartiorius, Stonehouse, UK) was used to remove the neuraminidase followed by  removal 
of excess APTS by a Discovery DPA-6S solid phase extraction cartridge (50 mg packing, 
Supelco, Bellefonte, PA). A flush of 95:5 (v/v) acetonitrile:water was used to prepare the 
cartridge prior to use. APTS was eluted from the extraction cartridge with a solution 
containing 95:5 (v/v) acetonitrile:water containing 50mM  trimethylamine. An aqueous 
solution of 50mM triethylamine was used to elute the retained glycans from the cartridge. 
The glycan solution was evaporated to dryness and the reconstituted in 100 µL deionized 
water and stored at -20 ℃.
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2.2.4 Phospholipid Preparation
Preparations of phospholipids were comprised of 5%, [DMPC]/[DHPC] (q value) = 0.5 
were used for coating of the capillary, which serves to suppress the electroosmotic flow, 
and to passivate the surface from nonspecific interactions. Another phospholipid 
preparation of a 10%,  q= 2.5, phospholipid solution was used for the separation media, 
due to the thermally-switchable gel-like viscosity  of the material. These phospholipids 
were prepared by weighing out the appropriate masses of dry DMPC and DHPC, then 
adding 100 mM aqueous MOPS buffered to pH 7. After the solution was thoroughly 
mixed, the preparation was subjected to a minimum of three freeze-thaw cycles and 
centrifuged for 10,000 rpm for ten minutes. The phospholipid preparation was stored at 
-20 ℃, and was thawed and vacuum degassed prior to use.
2.2.5 Capillary Electrophoresis
 Separations were performed using a P/ACE MDQ Capillary electrophoresis 
system (Beckman Coulter, Fullerton, CA) equipped with laser induced fluorescence 
detection (air cooled argon ion laser, λex = 488 nm, λem = 520 nm). The fused silica 
separation capillary had a 25 µm internal diameter and a 360 µm outer diameter 
(Polymicro Technologies, Phoenix, AZ) with an effective length of 50.0 cm and a total 
length of 60.2 cm. Capillaries were subject to the following flushing sequence daily: 1 M 
NaOH for 30 minutes at 170 kPa (25 psi), deionized water for 15 minutes at  170 kPa (25 
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psi), methanol for 15 minutes at  170 kPa (25 psi), and 15 minutes of water at 170 kPa (25 
psi). Following this flushing sequence, the capillary was passivated with a phospholipid 
coating with a 5%, q = 0.5 phospholipid preparation containing 1.25 mM calcium. This 
semi-permanent coating was applied for 20 minutes at 170 kPa (25 psi) followed by a 2 
minute MOPS flush at 170 kPa (25 psi) to remove excess phospholipid and  from the 
capillary. A brief pre-coat was applied prior to each run using the following protocol at 
170 kPa (25 psi) with the capillary held at 19℃: q = 0.5, 5% phospholipids for 3 minutes, 
MOPS for 2 minutes, and q = 2.5, 10% phospholipids for 3 minutes. If enzyme was being 
used in-capillary, an additional 3 minute 170 kPa (25 psi) MOPS flush was performed in 
the reverse direction before this sequence, to expel any enzymes from the capillary, and 
to prevent fouling of the capillary. When the room temperature was higher than 22 ℃, a 
portable air conditioner was used to provide ambient thermal control. Injections into the 
capillary were carried out in three steps. First, a plug a MOPS was injected into the 
phospholipid filled capillary (7 sec, at 6.9 kPa) at 19 ℃. The capillary temperature was 
then heated to 25 ℃, resulting in the viscosity  of the q = 2.5 10 % phospholipid filling to 
increase to a gel-like consistency. The glycan is then electrokinetically injected into the 
capillary. Finally a post-plug of MOPS was pressure injected (5 sec, 3 kPa). Separations 
were carried out at 400 V/cm under reversed polarity. Data collection and analysis were 
performed using 32 Karat Software version 5.0 (Beckman Coulter). Theoretical plates 
were calculated using 32 Karat Software using the “USP plates” criterion. 
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2.3 Results and Discussion
The results provided in this section have been peer-reviewed and published in reference 
[9].
2.3.1 Effects of Capillary Inner Diameter
 Previous experiments utilizing phospholipid additives were accomplished with a 
50 µm i.d., 30.2 cm effective length capillary [1], but should be compatible with varying 
capillary inner diameters, including 25 µm i.d.s.  The advantages of utilizing a smaller 
i.d. capillary  include reduced consumption of phospholipid additives as well as 
incorporated proteins. This advantage is explained further in Chapters 3 and 4 of this 
document. Reducing the i.d. of the capillary also results in a reduction of the separation 
current. The majority  of separations reported in this research were accomplished in a 25 
µm inner diameter. While separations with 75 and 100 µm i.d capillaries are feasible, they 
were not pursued. 
2.3.2 Optimization of Injection
  This protocol utilizes an aqueous pre-plug of MOPS into the phospholipid 
material before and after the analyte is electrokinetically injected.  The protocol was 
originally  reported by Luo et al. [1] for a 50 µm i.d., 30.2 cm effective length capillary, 
but was further optimized for a 25 µm i.d capillary. Experiments were conducted to 
determine optimum pre and post-plug sizes, as well as the effects of injection size on 
separation efficiency and area reproducibility.
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 The injection of a small plug of buffer prior to the electrokinetic injection of 
sample creates an ion depleted zone for the negatively charged glycans to inject into [7]. 
To determine if the volume of the buffer pre plug affects the plate count, two different 
plug sizes were compared for a 10 kV 3 sec injection of high mannose glycans from 
RNase B in a 30.2 cm capillary. The results of these separations are shown in Table 2-2. 
They  reveal no statistical difference until the plug size was less than 3 kPa (0.5 psi) 7 sec. 
Under these conditions the oligosaccharides could no longer be reproducibly injected. 
Therefore injections were accomplished with a 6.9 kPa (1psi) 7 sec, unless otherwise 
noted.
Table 2-1: Comparison of Pre-plug Size
Plug size Plates Area
10psi 7 sec 370,000 4600
1psi 7 sec 420,000 4300
0.5psi 5 sec 370,000 4800
Mannose 6 (from Rnase B), n = 1, Leff = 40.2cm, Lt = 
50.2cm, sample injected for 10kV 3 sec, Eapp = 400 V/cm, 
BGE=100mM MOPS pH 7. This data was reproduced with 
permission from [9]. Copyright 2011 American Chemical 
Society.
Table 2-2: Comparison of Two Pre plug Sizes
Plug size Time (RSD%) Area (RSD%) Plates (RSD%)
3 kPa (0.5psi) 7 sec 6.95 (1%) 92,000 (20%) 78,000 (4%)
6.9 kPa (1psi) 7 sec 6.85 (1%) 91,000 (20%) 81,000 (5%)
Mannose 6 (from RNase B), n = 3, Leff = 20.2 cm, Lt = 30.2 cm, sample injected for 
10kV 3 sec, Eapp = 400 V/cm, BGE=100mM MOPS pH 7.  Time is in minutes. This 
data was reproduced with permission from [9]. Copyright 2011 American Chemical 
Society.
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  The injection of a small plug of MOPS after the electrokinetic injection in the 50 
µm i.d. capillary prevents peak tailing [1], as a result of carryover of analyte [8]. No 
statistical difference in area or plate count was obtained with the inclusion of a post-
injection plug (as shown in Table 2-3). However, because the inclusion of a small post-
injection plug did not  increase the analysis time, and does prevent long-term 
contamination of the separation buffer vials, a (3 kPa (0.5psi) 5 sec) plug was used. 
Table 2-3.  Effect of Post plug size
Post Plug Time (RSD) Area (RSD) Plates (N)
wait 13.2 (1%) 49,000 (20%) 520,000 (4%)
0.5psi 5s + wait 13.1 (1%) 43,000 (7%) 520,000 (2%)
1psi 7s + wait 13.1 (1%) 44,000 (20%) 530,000 (3%)
5psi 5s + wait 13.1 (1%) 45,000 (20%) 530,000 (5%)
Mal 5 (from Maltoses), n = 3, Leff = 50.2cm, Lt = 60.2cm, sample injected for 10kV 3 
sec, Eapp = 400 V/cm, BGE=100mM MOPS pH 7. This data was reproduced with 
permission from [9]. Copyright 2011 American Chemical Society.
 
 The time of the electrokinetic injection affects separation efficiency, as the peak 
broadening associated with sample introduction is related to the analyte injection band 
size [10-12]. Therefore, the highest efficiency separations are obtained with the smallest 
possible injection volumes. However, the ramp time for applied voltage affects the peak 
area reproducibility. This is demonstrated in Table 2-4 using the glycans derived the 
RNase B, which compares three injections of varying injection voltage but identical 
duration. As the injection voltage is increased, the  width of injection band increases. This 
36
reduces the plate count, as the area increases. The highest plate count was obtained for a 
2 kV 9 sec injection. However, the area reproducibility of injections performed at 2 kV 9 
sec had a relative standard deviation of 20 %. 
Table 2-4. Effect of injection Size on Area Reproducibility
Injection Area (RSD) Plates (N)
2kV 9 sec 34,000 (20%) 97,000 (3%)
4kV 9 sec 89,000 (5%) 76,000 (5%)
6kV 9 sec 133,000 (5%) 48,000 (3%)
Mannose 6 (from RNase B), n = 5, Leff = 20.2cm, Lt = 30.2cm, other 
conditions as described in Table 1.  This data was reproduced with 
permission from [9]. Copyright 2011 American Chemical Society.
 The trade-off between precision and plate count is further demonstrated in Table 
2-5.  If the user requires highly efficient separations, an injection of 10 kV 3 sec may be 
used. However, if quantitative data is required, a 4 kV 5 sec injection will result in a 
reduced plate count, but area reproducibilities of 6 %. 
Table 2-5. Effect of Injection Size on Precision and Plate Count
Injection Time (RSD) Area(RSD) Plates (N)
10kV 3 sec 15.1 (0.1%) 16,000 (10%) 537,000 (2%)
4kV 5 sec 14.7 (1%) 28,000 (6%) 485,000 (6%)
Mannose 6 (from RNase B), n = 5, Leff = 50.2 cm, Lt = 60.2 cm, Eapp = 400 V/cm, 
anodic/cathodic reservoir contain 100 mM MOPS buffered at pH = 7, capillary filled 
with 10% q = 2.5 phospholipid as described in the text. This data was reproduced with 
permission from [9]. Copyright 2011 American Chemical Society.
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2.3.3 Effects of Capillary Length on Efficiency
 To characterize the effects of capillary length on the separation efficiency, 
branched glycans taken from RNase B (Table 2-6) and linear maltooligosaccharides 
(Table 2-7) were separated in capillaries with varying effective lengths. The total 
capillary length varied from 30.2 to 60.2 cm, which the effective capillary  length varying 
from 10.2 to 50 cm. Separations of the glycans were injected for 10 kV 3 sec and 
separated at an applied voltage of 400 V/cm. When the effective capillary  length was 
increased, the corresponding plate count also increased. This trend was equivalent for 
both the branched and linear glycans. When the total length of the capillary was kept 
constant, but the effective length was changed, the higher effective separation length 
resulted in a higher theoretical plate count. This was accomplished by performing 
separations on a capillary with a total length of 60.2 cm, but introducing sample from 
either end of the capillary, providing an effective length of either 10.2 or 50.0 cm. 
Interestingly, the gains in efficiency as a function of increasing effective length are not 
linear. This can be seen in both Tables 2-6 and 2-7 where the plates per meter also 
increase with increasing effective capillary  length. Based on this data, the optimum 
separation length was determined to be with a 50.0 effective, 60.2 cm total capillary 
length, which provided theoretical plate counts of more than a half a million plates
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. 
Table 6.  Effect of Length on Separation Efficiency 
Leff  (cm) Time (RSD)   Plates (RSD) Plates per meter (N/m)
10 3.11 (1%) 32,000 (3%)       320,000
20 6.05 (0.2%) 133,000 (2%)       665,000
30 8.88 (0.7%) 234,000 (3%)       780,000
40 12.14 (0.4%) 378,000 (1%)       945,000
50 15.1 (0.1%) 530,000 (2%)    1,060,000
Mannose 6 (from RNase B), n = 5, sample injected for 10kV 3 sec. The applied 
voltage was 400 V/cm. The anodic/cathodic reservoir contained 100 mM MOPS 
buffered at pH = 7, and the capillary was filled with 10% q = 2.5 phospholipid as 
described in the text. RSD = relative standard deviation. This data was reproduced 
with permission from [9]. Copyright 2011 American Chemical Society.
Table 7. Effect of Length on Separation Efficiency (linear glycan)
Leff  (cm) Time (RSD) Plates (N) Plates per meter (N/m)
10 2.74 (0.7%) 44,000 (5%) 440,000
20 5.41 (0.2%) 149,000 (1%) 745,000
30 7.85 (0.1%) 247,000 (2%) 823,000
40 10.75 (0.01%) 370,000 (3%) 930,000
50 13.38 (0.2%) 536,000 (1%)             1,070,000
Maltose 5 (from linear maltoses), n = 5, sample injected for 10kV 3 sec. The 
applied voltage was 400 V/cm. The anodic/cathodic reservoir contained 100 mM 
MOPS buffered at pH = 7, and the capillary  was filled with 10% q = 2.5 
phospholipid as described in the text. RSD = relative standard deviation. This 
data was reproduced with permission from [9]. Copyright 2011 American Chemical 
Society.
2.3.4 Effects of Electric Field Strength on Efficiency
 Separation efficiency  is increased in CE when the applied voltage is as high as 
possible without inducing band broadening due to Joule heating. The risk of Joule heating 
is especially relevant to the use of phospholipid additives due to the temperature 
dependent viscosity of the media. Therefore, the highest applied field strength that does 
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not lead to Joule heating will provide the best efficiency.  Because the maximum applied 
voltage for the Beckman P/ACE MDQ capillary electrophoresis instrumentation is 
limited to 30 kV, a shorter capillary  (40.2 cm, 25 µm) was utilized to provide a wide 
range of field strengths.  A plot of plate height versus the electric field strength is shown 
in Figure 2-2.  The field strengths range from 100 to 600 V/cm. and were based on the 
n=3 separation efficiencies of maltopentaose.  The lowest plate heights were obtained at 
field strengths between 350 V/cm and 450 V/cm.  This information is consistent with the 
separation suffering from longitudinal band broadening at field strengths at field 
strengths below 350V/cm ,  and Joule heating effects at field strengths above 450 V/cm. 
Therefore all glycan separations were performed at  an effective field strength of 400 V/
cm.
40
 Figure 2-2 displays a plot of separation efficiency  as a function of applied electric field. 
Each plotted data point is determined from three electrophoretic separations of 
maltopentaose. This data was reproduced with permission from [9]. Copyright 2011 American 
Chemical Society.
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2.3.5 Limits of Detection
 The limit of detection of this method was estimated for a 10kV 3 sec injection 
using the linear maltooligosaccharide, maltopentaose. This oligosaccharide was labeled 
with APTS as the limiting reagent. Assuming the labeling efficiency was 100%, a 300 
femtomolar sample of maltopenaose was electrokinetically injected to the separation 
capillary. This separation yielded a signal to noise (S/N) ratio of 60, and thus a limit of 
detection of 15 femtomolar.  
2.4 Conclusions
 This chapter demonstrates the further development of efficient separations for 
capillary electrophoresis with phospholipid-additives. These separations are 
accomplished without any covalent modification of the capillary, and can be 
accomplished in a variety of capillary  inner diameters. This i.d. compatibility is critical 
because modified capillaries smaller than 50 µm i.d. are not easily obtained 
commercially. As a 25 µm i.d. provided a reduction in reagent consumption and 
separation current, it  was chosen for continued studies of . The highest separations 
efficiencies were obtained in capillaries with the longest effective separation length. 
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Chapter 3
 
Optimization of In-Capillary Interactions of Glycans to 
Lectins and Enzymes 
45
3.1 Introduction
 Carbohydrates are vital to cellular biological processes where they play key roles 
such as cell-cell recognition, cell-matrix recognition, and cellular regulation [1]. 
However, the determination of the structural characteristics of glycoproteins is nontrivial, 
due in part because of the wide variability of glycosylation and the prevalence of 
isomeration. Additionally, a small changes in the glycan structure can significantly 
influence the biological activity of the glycoprotein. This is especially true for 
glycoproteins manufactured for therapeutic purposes, where changes in glycosylation 
may dramatically affect the overall pharmacological efficacy of the glycoprotein. 
Carbohydrate-specific proteins such as lectins and exoglycosidase enzymes have been 
shown to be effective methods of oligosaccharide characterization. By incorporating 
these proteins into the separations capillary, glycans introduced into it with the targeted 
structural features will be bound or enzymatically cleaved. This results in changes to the 
electropherogram by removing (for lectins) or shifting (for enzymes) the peak.  This 
chapter describes a means to incorporate lectins and enzymes into a phospholipid-filled 
capillary to rapidly  characterize and sequence glycan samples. The work described in this 
chapter has been published in [2][3].
46
3.1.1 Lectins 
 Lectins are plant and animal isolated proteins that bind to carbohydrates with high 
affinity. Lectins are of non-immune origin and have no catalytic activity and thus are 
unique from antibodies and enzymes in this regard [4].  The cellular functionalities of 
lectins vary and have been implicated in cellular recognition [5], the recognition of 
cellular hosts by viruses [6], cell growth and differentiation [7], as well as number of 
other functions.  The highly specific nature of lectins for a particular glycan 
characteristic, makes it useful for a number of biochemical applications. These 
applications include blood typing, glycan analysis, preparative scale isolation of 
glycoconjugates, as well as studies that focus on cellular agglutination and cellular 
separation and identification. The binding affinities of lectins (102 - 106 M-1) are not  as 
strong as that  of carbohydrate-binding antibodies (104 - 108 M-1), which provides a 
distinct advantage [8]. Unlike immunoaffinity interactions that may require harsh 
conditions to trigger release after binding,  the conditions for release of a glycoconjugate 
from a lectin is comparatively  mild, allowing for the release of intact glycoprotein or 
whole cell.   Lectins are commercially  available, and are produced from a number of 
naturally derived sources. 
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3.1.2 Mass Spectrometry
 Mass spectrometry is a powerful tool that has been extensively used in the study 
of glycans and glycoconjugates, and providing a basis for the structural characterization 
of the glycan structure. Both matrix-assisted laser desorption/ionization (MALDI) and 
electrospray  ionization offer unique advantages for the analysis of glycans [9]. However, 
determining glycan sequence with each method also has number of challenges. These 
include difficulties in elucidating the correct linkage of residues, and an inability to 
distinguish isomers. As a result, interpretation of these spectra often must be overcome 
with complicated analyses, often by  requiring sophisticated computational methods of 
bond linkage determination [10,11]. Challenges in ionization and detection are often due 
to the presence of additional negative charges, such as through the addition of sialyated 
species [12]. To provide better ionization for MS analysis, they must be derivatized 
through methods such as permethylation prior to analysis. The method of ionization can 
result in increased spectra complexity. Electrospray ionization spectra often are 
complicated by the appearance of different charge states, ion suppression,  and adduct 
formations, while MALDI ionization requires derivatization prior to analysis to prevent 
fragmentation, and to facilitate quantitative analysis [13]. Due to the complexity of most 
biological glycan samples, both methods often require analytical separations prior to 
ionization and analysis. While ESI methods can be readily coupled online to chemical 
separations methods such as CE and HPLC, MALDI methods must be coupled off-line. 
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 The difficulties in determining linkage, and in distinguishing between isobaric 
glycan isoforms have led to the enzymatic cleavage of these glycans prior to analysis. 
Mass spectrometry sequencing following enzymatic treatment has been utilized for both 
ESI coupled to ion trap [14,15] and MALDI coupled to time-of-flight mass analysis [16]. 
3.1.3 Exoglycosidase Enzymes 
 Exoglycosidase enzymes are glycosidic hydrolase enzymes that selectively cleave 
the terminal residues of glycans. In addition to monomer specificity, these enzymes can 
also be both position and linkage specific.  Exoglycosidases are readily  available through 
a number of commercial sources. While the use of these enzymes for benchtop  analyses 
have been well documented, these reactions face a number of obstacles. The incubation 
times required for glycan hydrolysis in free solution can be lengthy, and the amounts of 
glycan and enzyme required per analysis can be cost prohibitive. Reaction products must 
be analytically separated from the unreacted original substrate. Furthermore, errors 
related to sample handling can affect the overall performance of the final method. 
Therefore ideal methods that utilize exoglycosidases for glycan analysis should use low 
amounts of glycan and enzymes, be low volume, and should be integrated into the 
methods of separation to provide reduced sample handling and losses due to sample 
transfer. 
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3.2 Experimental
3.2.1 Chemicals and Materials:
 Reagents were obtained from a variety  of manufacturers. Sigma Aldrich (St. 
Louis, MO, USA) was the source for asialofetuin from fetal calf serum, 3-(N-
morpholino)-propanesulfonic acid (MOPS), calcium chloride dihydrate, 
maltooligosaccharide standards, sodium chloride, and sodium hydroxide. Methanol and 
α1-acid glycoprotein (AGP) were purchased from EMD Biosciences (La Jolla, CA). 
Ethanol was obtained from AAPER Alcohol (Shelbyville, KY). 1,2-dimyristoyl-sn-
glycero-3-phosphocholine (DMPC) and 1,2-dihexanoyl-sn-glycero-3-phosphocholine 
(DHPC) were obtained from Avanti Polar Lipids (Alabaster, AL). 1-aminopyrene-3,6,8-
trisulfonic acid (APTS) was purchased from Biotium (Hayward, CA). Sodium 
cyanoborohydride (NaCNBH3) was acquired from Strem Chemicals (Newburyport, MA). 
Triethylamine, acetonitrile, and citric acid were acquired from Fisher Scientific 
(Pittsburgh, PA). Ribonuclease B (Rnase B), α1-2,3 mannosidase, β1-4 galactosidase, 
neuraminiase, β-N-acetylglucosaminidase, and a peptide N-glycosidase (PNGase F) kit, 
were obtained from New England Biolabs (Ipswich, MA). A G7 10X reaction solution 
composed of 0.5M sodium phosphate buffered at pH 7.5, a glycoprotein denaturing 
solution containing 5% sodium dodecyl sulfate (SDS), and 0.4 dithiothreitol (DTT), and 
10% solution of nonionic surfactant NP-40 were included in the PNGase F kit. A G1 10X 
reaction solution composed of 0.5M sodium citrate buffered at pH 6 was provided in the 
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neuraminidase kit. An Elga Purelab ultra water system (Lowell, MA) was used to provide 
deionized water.
3.2.2 Preparation and Derivatization of Glycan Standards
 Glycans derived from glycoproteins (Rnase B, asialofetuin, and α-acid 
glycoprotein) were prepared as follows. Glycans were removed from protein sources 
using a PNGase F kit using a protocol based on the kit from the manufacturer. Briefly the 
protein is denatured using a solution containing SDS and DTT and heating at 95℃ for 10 
minutes. The nonionic surfactant NP-40 is then added to the solution to prevent the DTT 
from denaturing the enzyme PNGase F, which immediately added afterward. This 
reaction was incubated at 37℃ overnight, rather than the 2 hours suggested by  the 
protocol. The next  day, a 3X volume of ice-cold ethanol was added to precipitate the 
protein. The solution was centrifuged at 4℃ at 10 000 rpm for 10 minutes. The liquid 
fraction containing cleaved glycans was dried using a Savant SpeedVac concentrator 
(ThermoScientific, Waltham, MA). The dried glycans , or dried glycan standards were 
reconstituted in 1µL  of a 0.2M solution of APTS dissolved in 1.2M  citric acid, along 
with 1µL of 1 M  NaCNBH3 in deionized water. The solution was thoroughly mixed 
before being incubated overnight  at  37℃. 100µL of deionized water was used to stop the 
reaction. If needed, the sialic acid was removed by  adjusting the pH of the glycan 
solution to 6 with sodium hydroxide then incubating it overnight with neuraminidase. If 
necessary, a 10kDa molecular weight cut off filter (Sartiorius, Stonehouse, UK) was used 
to remove the neuraminidase followed by removal of excess APTS by a Discovery 
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DPA-6S solid phase extraction cartridge (50mg packing, Supelco, Bellefonte, PA). A 
flush of 95:5 (v/v) acetonitrile:water was used to prepare the cartridge prior to use. APTS 
was eluted from the extraction cartridge with a solution containing 95:5 (v/v) 
acetonitrile:water containing 50mM triethylamine. An aqueous solution of 50mM 
triethylamine was used to elute the retained glycans from the cartridge. The glycan 
solution was evaporated to dryness and the reconstituted in 100 µL deionized water and 
stored at -20℃. 
3.2.3 Preparation of Phospholipid Additive
 Preparations of phospholipids were comprised of 5%, [DMPC]/[DHPC] (q value) 
= 0.5 were used for coating of the capillary, which serves to suppress the electroosmotic 
flow, and to passivate the surface from nonspecific interactions. Another phospholipid 
preparation of a 10%,  q= 2.5, phospholipid solution was used for the separation media, 
due to it’s thermally-switchable gel-like viscosity. These phospholipids were prepared by 
weighing out the appropriate masses of dry DMPC and DHPC, then adding 100mM 
aqueous MOPS buffered to pH 7. After the solution was thoroughly mixed, the 
preparation was subjected to a minimum of three freeze-thaw cycles and centrifuged for 
10,000 rpm for ten minutes. The phospholipid preparation was stored at -20℃, and was 
thawed and vacuum degassed prior to use. 
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3.2.4 Capillary Electrophoresis
 Separations were performed using a P/ACE MDQ Capillary electrophoresis 
system (Beckman Coulter, Fullerton, CA, USA) equipped with laser induced 
fluorescence detection (air cooled argon ion laser, λex = 488 nm, λem = 520 nm). The 
fused silica separation capillary  had a 25 µm internal diameter and a 360 µm outer 
diameter (Polymicro Technologies, Phoenix, AZ, USA) with an effective length of 50.0 
cm and a total length of 60.2 cm. Capillaries were subject to the following flushing 
sequence daily: 1M NaOH for 30 minutes at 170kPa (25 psi), deionized water for 15 
minutes at 170kPa (25 psi), methanol for 15 minutes at 170kPa (25 psi), and 15 minutes 
of water at 170kPa (25 psi). Following this flushing sequence, the capillary was 
passivated with a phospholipid coating with a 5%, q=0.5 phospholipid preparation 
containing 1.25mM  calcium. This semi-permanent coating was applied for 20 minutes at 
170kPa (25 psi) followed by a 2 minute MOPS flush at 170kPa (25psi) to remove excess 
phospholipid and  from the capillary. A brief pre-coat was applied prior to each run using 
the following protocol at  170kPa (25 psi) with the capillary held at 19℃: q=0.5, 5% 
phospholipids for 3 minutes, MOPS for 2 minutes, and q=2.5, 10% phospholipids for 3 
minutes. If enzyme was being used in-capillary, an additional 3 minute 170 kPa (25 psi) 
MOPS flush was performed in the reverse direction before this sequence, to expel any 
enzymes from the capillary, and to prevent fouling of the capillary. When the room 
temperature was higher than 22℃, a portable air conditioner was used to provide ambient 
thermal control. Injections into the capillary  were carried out in three steps. First, a plug a 
MOPS was injected into the phospholipid filled capillary (7s, at 6.9 kPa) at 19℃. The 
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capillary temperature was then heated to 25℃, resulting in the viscosity of the q=2.5 
10% phospholipid filling to increase to a gel-like consistency. The glycan is then 
electrokinetically injected into the capillary. Finally a post-plug of MOPS was pressure 
injected (5 s, 3 kPa). Separations were carried out at 400 V/cm under reversed polarity. 
Data collection and analysis were performed using 32 Karat Software version 5.0 
(Beckman Coulter). 
3.2.5 Enzymatic Reactions
 Enzymatic reactions were either conducted in a bench-top  reaction, or in capillary. 
Benchtop reactions of enzyme were conducted at small volume (<100 µL) in ~0.2 mL 
polypropylene tubes in the buffers and conditions suggested by manufacturers. All 
incubations, unless otherwise noted, were completed at 37℃ overnight. Enzymatic 
reactions completed in-capillary were accomplished by injecting a small plug of the 
enzyme solution into the capillary at 19℃, prior to increasing the temperature of the 
capillary to 25℃. Glycans were injected into the capillary at this elevated temperature, 
and electrokinetically moved at  a low voltage into the enzyme plug prior to incubation 
and separation, as noted in the text.  
3.3 Results and Discussion
The results in this section have been peer reviewed and published in references [2] and 
[3]. 
54
3.3.1 Methods of Glycan Identification using Standards 
 Glycan standards can be used to test  the performance of an analytical method. 
Standards may also be used to confirm the identity of a glycan of interest. In this work, 
both the glycan to be analyzed and the standard glycan are labeled with the fluorescent 
tag, APTS. Migration times of the two are then either compared, or the standard is added 
to the glycan sample to assign peak composition. Glycan standards can be purchased 
commercially, or can be derived from common glycoproteins. Examples of glycoproteins 
well-charaterized in literature and thus used as standards are the high mannose glycans 
from ribonuclease B (RNase B), as well as the complex-type glycans from bovine serum 
fetuin  and α-acid glycoprotein (AGP). Figure 3-1 displays a separation of glycan 
standards used in some of the studies completed for this work. These glycans include the 
linear maltose oligosacchardies (G4, G5, G6, and G7) that were purchased, glycans 
(Man5, Man6, Man7, Man8, Man9) taken from Ribonuclease B, and branched di, tri, and 
tetraantennary  complex-type glycans from the protein α-acid glycoprotein (AI, AII, AIII, 
AIV, and AV). Sialic acid from complex-type glycans was commonly removed prior to 
analysis as sialyation drastically increases the complexity  by  adding additional charge 
and thus variation electropherogram. The Figure 3-1 glycans provide 14 standard glycans 
all with different glycoform structural types and serve well as inexpensive methods of 
structural confirmation. Due to the high separation efficiencies described in Chapter 2, 
these glycans can be efficiently separated from each other, and with very small variances 
in migration time , making migration-based identification a feasible method.
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Figure 3-1 displays an electropherogram of glycan standards used by the Holland 
group. Glycans include those from linear maltooligosaccharides as well as branched 
glycans from glycoproteins Rnase B and AGP. This figure was reproduced with 
permission from [3]. Copyright 2011 American Chemical Society.
 While the use of glycan standards is a frequently  used approach for peak 
identification, it suffers from two major drawbacks. The first drawback is that, simply, the 
needed glycan standard may not be available to the user through a commercial or 
glycoprotein source. The second is due to the increased cost that comes from purchasing, 
each particular glycan standard that is of interest. Obtaining and labeling each standard 
can be costly  and commercial availability of such standards is often a major challenge to 
this method of identification. While glycan standards can be obtained from glycoprotein 
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sources, the increased time and cost in deglycosylating, labeling, and purifying these 
glycans can be prohibitive, and the number of glycoproteins that are well characterized is 
few. 
3.3.2 Utilization of Lectins and Enzymes for Glycan Characterization
 An alternative method of elucidating structure of a glycan of interest is through 
the use of highly  specific proteins, such as lectins and enzymes. These proteins will 
selectively bind or enzymatically cleave only  the glycans that have the targeted 
characteristic. This method has been frequently used on the bench-top for down-stream 
analysis using separations techniques such as HPLC and CE, and mass spectrometry. 
However, this method is hindered by  the amounts of enzyme or lectin consumed per 
analysis, as well as the lengthy incubation times that are a result of free-solution 
reactions. Incorporating these proteins within the capillary allows for the reaction volume 
to be reduced, and for the incubation times to be reduced by increasing the ratios of 
enzyme to glycan per analysis. 
 In-capillary analyses were performed using a commercially  available, automated 
capillary electrophoresis system (Beckman P/ACE MDQ). This system is equipped with 
temperature-programmable storage for samples and reagents. Although the practical 
volume limitations of the Beckman P/ACE MDQ are 20 µL, the actual amount of lectin 
injected into the capillary is in the nanoliter range per analysis. A 1.5 psi, 15 sec injection 
into a 25 µm inner diameter, 60 cm capillary is only 2 nL. In the 25 µm i.d. capillary this 
plug is only  ~0.5cm long and is less than 1% of the length of the total capillary. An 
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extensive flush in the reverse direction is used prior to each analysis to prevent 
contamination from run to run. Additionally, it  is common practice to complete a “blank” 
reaction in-between lectin or enzyme reactions to ensure this.
3.3.3 In-Capillary Reactions of Glycans to Lectins
 The process of in-capillary incorporation and interaction with glycan is depicted 
conceptually in Figure 3-2. Prior to analysis the capillary is prepared by briefly coating, 
flushing, then filling the the capillary phospholipid at 19℃. At this temperature, the 
viscosity  of the phospholipid is similar to that of water, and a small plug of lectin may be 
hydrodynamically injected into capillary. This lectin plug is bracketed by two small plugs 
of separation buffer to prevent the cross-contamination of the lectin with any  of the other 
vials. The temperature of the capillary is then increased to 25℃, resulting in the 
increased viscosity of the phospholipid and the entrapment of the protein lectin within the 
capillary. Because the phospholipid material is biocompatible, this entrapment procedure 
serves to immobilize the protein without denaturing it. At this increased temperature, the 
glycans are injected into the capillary and separated under reversed polarity  (usually 
400V/cm). The glycans are separated in the absence (top figure) and presence (bottom 
figure) of lectin. When lectin is incorporated into the separations capillary, glycans 
specific for the lectin are bound, and therefore do not migrate to the detection window. 
Thus the incorporation of lectins into the capillary is quick method to discern structural 
characteristics and can even be used to simplify complex electropherograms by 
selectively removing groups of glycans from analysis. 
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3.3.4 Concanavalin A
 Concanavalin A (ConA) is a lectin derived from Canavalia ensiformis (jack-bean) 
that is specific for glucose and mannose resides. It has been used in a number of studies 
for the analysis of mannose-rich glycans, including methods of capillary affinity 
electrophoresis  [17] and lectin-arrays [18,19].
 A small plug (1psi 7 sec) of 1mg/mL (~9 µM) Concanavalin A in pH 6,  2-(N-
morpholino)ethanesulfonic acid (MES) was used for the in-capillary  analysis of high 
mannose glycans from the standard glycans also shown in Figure 3-1. The glycan was 
separated through the capillary as normal, with no incubation or wait steps. Figure 3-3 
shows this electropherogram (top trace), as well as an electropherogram of the same 
Figure 3-2 displays a schematic of how plugs of lectins can be incorporated into a 
separations capillary. The top figure shows how glycans (colored bands) would 
separate in a capillary with no modifications. The bottom figure shows how glycans 
would separate in a capillary with a plug of lectin specific for a single (green) 
glycan. As the glycans are separated, and pass through the plug, the species with 
the chosen characteristic are bound to the lectin and do not migrate.
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glycans through a capillary containing only a buffer blank (pH 6 MES)(bottom trace). No 
incubations were necessary for the binding of these glycans to the lectin. Concanavalin A 
selects for mannose, and highly-branched mannose, and therefore bound to the high-
mannose glycans from Rnase B (Man5, Man6, Man7, Man8, and Man9). It is interesting 
to note that, despite the relative abundance of these glycans, a high specificity of the 
lectin to branch mannose is obtained. This is especially true for the branched mannose 
Man5 in comparison to the linear heptamaltose, G7. While the relative concentration of 
Man5 is high in comparison to G7, the linear glycan unaffected by the lectin. The 
diantennary  complex-type glycan AI from α-acid glycoprotein does respond to ConA, but 
could be completely removed from the separation with higher concentrations of ConA. 
This is because ConA will bind to the Man3 core the glycan. [17].
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Figure 3-3 displays an electropherogram of glycan standards (high mannose 
glycans from RNase B, complex-type glycans from AGP, and linear maltoses) 
separated in a capillary containing either a buffer blank, or 1mg/mL Concanavalin 
A. Separations were completed in a 60.2 cm, 25 m. i.d. capillary at a field strength 
of 400 V/cm. This figure was reproduced with permission from [3]. Copyright 2011 
American Chemical Society.
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3.3.5 Use of Enzymes for In-Capillary Analysis
 The phospholipid media can be utilized to incorporate proteins into the capillary 
without subsequent covalent modification or denaturation. This makes this media 
especially useful for the incorporation of bio-active proteins such as exoglycosidase 
enzymes. These enzymes exhibit great sensitivity to both residue types (e.g. mannose, 
galactose), linkage position (e.g. 1-3, 1-4), and linkage type (e.g. α, β). Exoglycosidases 
are well characterized and commercially available through a number of sources. Unlike 
the use of lectins in-capillary, the selected glycan is not retained in the protein plug inside 
of the capillary. Because the exoglycosidase removes terminal glycan residues, the rest of 
the glycan is still fluorescently tagged, but now smaller in size. This results in a change of 
electrophoretic mobility, and thus the migration. In this analysis method, the glycans with 
the desired characteristics will be identified by a shift in the migration time. This is 
demonstrated conceptually in Figure 3-4.
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Figure 3-4 displays a schematic of how plugs of enzymes can be incorporated into 
a separations capillary. The top figure shows how glycans (colored bands) would 
separate in a capillary with no modifications. The bottom figure shows how glycans 
would separate in a capillary with a plug of enzyme specific for a single (pink) 
glycan. Following incubation, this glycan is truncated by the enzyme, and therefore 
migrates at a different velocity.
 The process of positioning, incubating, then separating the glycan is part of a 
three-step process. The enzyme is introduced into the capillary using the same methods as 
lectin introduction mentioned previously, and immobilized within the capillary  at 25℃ 
by the highly viscous phospholipids. The glycan is then injected into the capillary and 
moved into the enzyme plug with a brief electrokinetic “push” at low voltage (10kV 30 
sec). The glycans are incubated in the enzyme plug for a specified amount of time, and 
the reaction products are separated and detected in the capillary. A benefit of using in-
capillary exoglycosidase reactions over bench-top free solution reactions is that the 
reaction volume is small (~2 nL). Although commercial exoglycosidase kits require 1 
hour of incubation time, none of the in-capillary incubations presented in these studies 
were longer than 20 minutes. Additionally, because the incubation step in the capillary is 
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part of the program, a series of experiments with varying incubation times can be 
performed with the same sets of enzyme and glycan. This includes the monitoring of both 
the disappearance of substrate, the appearance of product, and the appearance of 
intermediate products, if possible (Figure 3-5).
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Figure 3-5 displays a schematic of how in-capillary plugs of enzymes can be 
utilized to monitor the formation of glycan enzymatic products. The top figure shows 
how glycans (colored bands) would separate in a capillary with no modifications. 
The other figures demonstrate the progressive depletion of the original glycan, and 
the accumulation of the glycan products. 
3.3.6 Mannosidase
 High-mannose glycans are of interest in a number of fields of study; for example 
high-mannose glycans have been linked as biomarkers for a number of health-related 
issues such as breast cancer [20].  To investigate high mannose glycans, the enzyme 
α1-2,3 mannosidase was used for in-capillary studies. This enzyme selectively cleaves 
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α1-2 and α1-3 mannopyranosyl residues that are commonly found on high-mannose 
residues, and would eventually result in a final product consisting of a trimannose core 
with a number of α1-6 mannoses residues attached. Because these linkages are specific 
for high-mannose and high-mannose hybrid glycans, this enzyme can be used to confirm 
structure along with the lectin concanavalin A. 
 Figure 3-6 demonstrates how this enzyme can be used as a method to distinguish 
unresolved glycans. High mannose glycans from Rnase B, as well as linear 
maltooligosaccharides  were separated in a 40 cm, 50 µm inner diameter  capillary  coated 
and filled with phospholipid. In Figure 3-6-A, the glycan peaks for Man5 and 
heptamaltose have overlapped and thus are indistinguishable. By separating these glycans 
after increasing incubation times in-capillary, the peak corresponding to mannose 5 
decreases in area, revealing the identity of the peak. The linear maltoses are not cleaved 
by this enzyme and migrate with the same electrophoretic velocity  as those separated in 
the capillary  in the absence of enzyme. The product peak, which is believed to be from 
the cleavage of the α1-3 mannose residue attached directly  to the trimannose core, forms 
almost completely after 15 minutes, rather than the 1 hour required for the protocols 
provided by the manufacturer. The 20 µL samples of both glycan and enzyme may be 
used for multiple reactions, and under different incubation conditions. 
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9electropherograms in Figure 6 acquired at 25 °C contain a malto-
oligosaccharide ladder and glycans derived from RNase B injected
into a capillary loaded with phospholipid. The blank electrophero-
gram in trace A, which serves as a control, is obtained with no
enzyme in the capillary and a 15 min delay after sample is injected.
The separations in traces B, C, and D incorporate a phospholipid
plug containingR1-2,3mannosidase, but the incubation time following
sample injection is 5, 10, and 15 min, respectively. The decrease in
peak area of Man5 seen in traces B, C, and D in the presence of the
enzyme provides further confirmation of the analyte identity. Under
similar conditions employed for phospholipid separations, the intro-
duction of R1-2,3 mannosidase in bare fused silica capillary did not
result in effective cleavage of the Man5 sugar. Both R1-2,3 mannosi-
dase and Con A could successfully be introduced in capillaries coated
with phospholipid coating but lacking phospholipid additive in the
running buffer. However, the separation efficiency is worse.
CONCLUSIONS
This article demonstrates the use of phospholipid additives for
efficient glycan separations. The separation is accomplished without
covalent modification of the capillary surface to suppress electroos-
motic flow. The most efficient separations were obtained with a q )
2.5-10% preparation and can be accomplished in a 50 or 25 µm inner
diameter capillary. A benefit of phospholipid media is the ease with
which it can incorporate carbohydrate-binding lectin as well as
enzymes specific to cleave mannose residues to assist in the
structural elucidation of unknown glycans. The elimination of covalent
surface modification and the ease with which the preparation is
introduced into separation capillaries at low temperature (and low
viscosity) make it particularly interesting for microfluidic separations
or separations. Continued characterization of preparations of different
composition and hydration is currently underway to expand the
application of this additive and determine if other separation mech-
anisms may be implemented with phospholipids.
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Figure 5. Additional separation selectivity achieved when con A is
integrated into the phospholipid media prior to injection. The separation in
trace A was obtained with a blank phospholipid plug lacking ConA. The
separation in trace B was obtained with the ConA plug, which captured the
high mannose glycans derived from RNase B. The separation conditions
are identical to that obtained in Figure 2B. Note that the use of pressure to
introduce the ConA plug decreases the migration times relative to that in
Figure 2B and parts A and B of Figure 4.
Figure 6. Integration of an enzyme (R1-2,3 mannosidase) in the
separation to probe structural features of glycans. The separation in
trace A was subject to 15 min incubation with no mannosidase. The
lower electropherograms are obtained following an incubation time
of 5 (B), 8 (C), and 15 min (D) with the enzyme. The separation
conditions are identical to that obtained in Figure 2, trace B.
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Figure 3-6 demonstrates how the enzyme  α1-2,3 mannosidase can be used for in-
capillary analysis of glycan samples. A sample containing high-mannose sugars 
from Rnase B and lin ar maltoses was separ ted following various i cubation 
times in a plug of α1-2,3 mannosidase, resulting in the progressive cleavage of the 
Mannose 5 glycan, and the formation of its reaction product, which overlaps with 
the G6 peak. This figure was reproduced with permissio  fro  [2]. Copyright 2010 
American Chemical Society.
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3.3. 7 Galactosidase
 Galactose is one of the most common glycan residues in complex-type 
glycosylation, making it an important feature analyze. In addition to a number of general 
β-galactosidase enzymes, positionally  specific galactosidase enzymes are readily 
available including those that target β1-3, β1-4, β1-3,4,6, and β1-3,6 linkages. β1-4 
Linked galactose, a common terminal residue found in complex-type glycans, was the 
target of an on-line reaction using the enzyme β1-4 galactosidases. This enzyme was used 
to probe a solution of complex-type glycans from asialofetuin, a desialated version of 
bovine fetuin (Figure 3-7). Asialofetuin has three glycan structures, diantennary and 
triantennary structures that are identical to that as glycan from AGP (AI and AII), as well 
as a isoform of AII known as FII. FII has an identical structure to that of AII, with the 
exception that one of the glactose residues is attached with a β1-3 rather than β1-4 
linkage. This small change in overall glycan structures makes the resolution of these two 
isoforms difficult for most separations methods and speaks to the ability of phospholipid 
additives for high resolution and efficiency separations.  Figure 3-7 also demonstrates 
how, with different incubation times, the progressive disappearance of the substrate and 
appearance of product peaks can be monitored using the same initial samples of enzyme 
and glycan. 
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Figure 3-7 demonstrates how the enzyme  β1-4 galactosidase can be used for in-
capillary analysis of glycan samples. A sample containing complex-type glycans 
from bovine asialofetuin was separated following various incubation times in a plug 
of β1-4 galactosidase, resulting in the progressive cleavage of the β1-4 galactose 
monomers from the AII and FII glycans, and the formation of its reaction product. 
This figure was reproduced with permission from [4]. Copyright 2011 American 
Chemical Society.
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3.3.8 Neuraminidase 
 The existence of sialic acid can greatly  complicate the separation and 
identification of glycans for a number of analytical methods including liquid 
chromatography  and mass spectrometry. Sialic acid residues provide additional negative 
charge to the glycan. Sialic acids are also thermally labile and can detach following 
application of heat and acid. Often, the sialic acid content may analysis to analysis.  Mass 
spectrometric methods of analysis often require methylation and derivatization of sialic 
acids to prevent  their detachment prior to analysis. The affect of sialic acids are 
demonstrated in Figure 3-10-A, where glycans from α acid glycoprotein (AGP) are 
separated without prior removal of the sialic acid. Although there are only 5 major forms 
from AGP, the number of variable forms from sialic acid results in the number of peaks in 
the electropherogram. Therefore, it is common practice to remove sialic acids from 
glycans prior to analysis, by incubating the glycan solution with the enzyme 
neuraminidase. By incorporating this enzyme in-capillary, a simpler electropherogram 
can be obtained without extended incubation times. 
 Neuraminidase cleaves terminal sialic residues rapidly. On-line incubation times 
of 5 minutes or less are sufficient to remove all sialic acid. The desialylation of AGP 
shown in Figure 3-10-B was completed after a 5 minute incubation. Neuraminidase can 
also be incorporated with other enzymes as a discrete plug, or as part of an “enzyme 
cocktail” plug, where the enzyme is mixed with another prior to injection.
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3.3.9 Multiple enzyme Methods
 Exoglycosidase enzymes selectively target the terminal residues of a glycan. 
Therefore multiple enzymes can be used in combination to systematically  determine the 
full structure of  the glycan. In a bench-top analysis, this is accomplished by  sequentially 
treating the glycan with multiple enzymes, sequentially. The first enzyme is added, 
reacted, and the products are analyzed, then the sample is interacted with the second 
enzyme and so on. By scaling this model to the microscale, numerous experiments may 
be conducted using a single glycan samples and pristine solutions of enzymes, with the 
enzymatic reaction being completed within the capillary. 
3.3.10 Off-line sequencing model: AGP
 Enzymes can be utilized in combination to progressively clip away layers of 
residues, revealing the overall structure of the total glycan. This process is demonstrated 
for a single glycan (AV) in Figure 3-8. To discern the structure of this glycan, 
exoglycosidases are systematically applied to the glycan to remove each outer layer of 
residues with analysis in between each step. If CE is utilized for these analysis steps, the 
cleaved glycan will respond to by a different migration time, as the electrophoretic 
mobility  has changed in response to the truncated glycan. With the exception of 
desialation, which removes additional negative charge in addition to the residue, all of 
these cleavage steps result in an increased electrophoretic mobility and thus a shorter 
migration time. A greater migration shift can reveal the number of residues that have been 
removed during each step.
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 To demonstrate how these enzymes can used to sequence glycans derived from a 
glycoprotein, a multi-step enzymatic reaction on the bench-top  was conducted using the 
carbohydrates derived from α acid glycoprotein (AGP). The original, sialylated glycans 
are shown in Figure 3-9-A. When this glycan sample is modified with the enzyme 
neuraminidase the negatively charged sialic acid residues are removed, resulting in a 
reduced charge to size ratio and a longer migration time. Because this source of variable 
charge is removed, the five major glycoforms of AGP are shown in the resulting 
electropherogram, Figure 3-9-B. This glycan solution is then reacted with α fucosidase, 
with the resulting electropherogram shown in Figure 3-9-C. This affects the two glycans 
containing fucose (AIII and AV) and the reaction products collapses into the AII and AIV 
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Figure 3-8 demonstrates how multiple enzymes can be used in conjunction to 
determine the sequence of a complex glycan. The complex-type glycan shown (AV 
from AGP) has sialic acid, galactose, acetylglucosamine, and fucose glycan 
residues all attached to it’s mannose core. By using a number of enzymes in 
conjunction with each other the structure of the original glycoform can be deduced. 
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glycans. The sample is then reacted with β1-4 galactosidase with the results shown in 
Figure 3-9-D. All of the galactose in AGP are removed, resulting in dramatic migration 
shifts in the three remaining peaks.  The resulting solution is then reacted with β-N-
acetylglucosaminidase with the results shown in Figure 3-9-E. This reaction results in a 
single product, as all glycans have been cleaved down to the common, N-glycan 
trimannose core. The peak labeled with an asterisk (*) is a byproduct of the APTS 
labeling reaction and was used in this experiment as a migration time standard. 
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Figure 3-9 demonstrates how multiple enzymes can be used in conjunction to 
determine the sequence of a complex glycan. Glycans derived from AGP were 
progressively treated with the exoglycosidases neuraminidase, α fucosidase, β1-4 
galactosidase, and β-N-acetylglucosaminidase. These reactions progressively clip 
away successive layers of glycans until that all that remains is the trimannose core 
(shown in Figure 9-E)
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3.3.11 In-Capillary Sequential Enzymatic Reactions:
 The use of multiple enzymes that target only the terminal glycan residues can be 
used to glean structural information. However, this approach requires significant amounts 
of enzyme and sample The increased time to perform all of these bench-top enzymatic 
reactions is also a disadvantage. By  incorporating these enzymes into the capillary, these 
sequential analyses can be completed without utilizing the entire glycan sample or 
consuming significant volumes of enzyme. A glycan sample can be used for numerous 
analysis without affecting the original sample. Because the interaction with protein 
occurs in the separation capillary, no sample cleanup following the enzymatic reaction is 
necessary. 
 To demonstrate how multiple-enzyme plugs inside of the capillary can be utilized 
to discern structure, the two enzymes neuraminidase and β1-4 galactosidase were use 
separately  and together to probe solutions of glycans from AGP. Prior to injection of the 
glycan into the capillary  two discrete plugs are pressure injected into the capillary, 
separated by  a small plug of of buffer. The glycan is injected into the capillary then 
electrokinetically moved onto the first plug of enzyme and incubated. The glycan is then 
electrokinetically moved onto the second plug, incubated, then separated through the 
capillary.  The resulting electropherograms are shown in Figure 3-10. The first trace 
shows a separation of glycans from AGP through a capillary that contains no enzyme 
only blanks consisting of pH 6 citrate buffer. The many sialyated glycans can be seen by 
this electropherogram. These sugars were incubated for 5 minutes in a small plug of the 
enzyme Neuraminidase prior to the separation step. The five major desialylated. 
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glycoforms as seen in Figure 3-10-B. To determine the galactose content of these five 
glycoforms, the final trace demonstrates the use of two enzymes. In this 
electropherogram, glycans are injected and moved onto a plug of neuraminidsae, 
incubated for 5 minutes, then moved onto a plug of β1-4 galactosidase, incubated for 10 
minutes, then separated through the rest  of the capillary. As can be seen in figure 3-10-C, 
all of the glycans have been shown to be affected by the enzyme, by both the reduction in 
peak area, as well as by the formation of product peaks. 
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Figure 3-10 demonstrates how multiple enzymes with a separation capillary to 
sequentially remove terminal glycan residues, determining the overall structure of 
the glycan. Figure 10-A demonstrates an electrophoretic separation of glycans from 
AGP, that are sialyated. These highly complex glycans are greatly simplified when 
they are enzymatically treated with the enzyme Neuraminidase in-capillary for 5 
minutes. (Figure 10-B). When the glycans are are injected then injected for 5, then 
10 minutes in Neuraminidase and β1-4 galactosidase respectively, it can be noted 
that all major isoform glycans react. This indicates that all major isoforms of AGP 
contain sialic acid and β1-4 galactose
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3.4 Conclusions 
 The incorporation of glycan-specific proteins such as lectins and enzymes is a 
useful approach to elucidate glycan structure and composition. Phospholipid additives 
support the incorporation of protein-based selection agents without the need for covalent 
modification. This method has been shown to be effective in a variety of capillary  inner 
diameters. Utilization of an in-capillary  approach to lectin capture and enzymatic 
cleavage has a number of advantages of bench-top analyses including reduced reaction 
times, reduced consumption of reagents, and the utilization of a single sample of glycans 
for a multitude of analyses. The lectin concanavalin A, as well as the enzymes α1-2,3 
mannosidase, neuraminidase,  and β1-4 galactosidase were all used to demonstrate how 
in-capillary interactions can be used to probe solutions of glycans. 
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Chapter 4 
Applications of Method to Biological Samples: MCF7 
and Trastuzumab 
81
4.1 Introduction:
 Glycosylation exists as one of the primary post-translational modifications of 
proteins, and has extensive biological implications. Glycosylation also plays a vital role 
in the functionality of these proteins, as changes in the glycan structure can result in 
altered protein structure and changes in cellular signaling. This is especially important in 
the search for biomarkers of disease and the development of biological therapeutics such 
as IgG antibodies. This chapter covers how phospholipid-assisted capillary 
electrophoresis can be utilized to efficiency separate and analyze glycans, as well as to 
characterize these two samples by  incorporating lectins and exoglycosidase enzymes into 
the capillary. Cancerous tissues have been known to display  abherrent glycosylation [1]. 
Therefore the method was used to analyze the total glycan content from immortalized 
breast cancer cell line MCF7. This data has been published in  reference [2]. This method 
was also applied to analysis of glycans from the therapeutic antibody Trastuzumab 
(Herceptin®), a monoclonal antibody whose glycosylation has been well characterized 
[3].  This data has been published in reference [4]. 
4.1.1 Glycomics and Clinical Biomarker Research
 The total glycan content of a cellular sample can host a diverse variety  of 
oligosaccharides. Glycoproteins in eurkaryotic systems occur in all cellular compartments 
where they are attached to linked to peptides through serine or threonine (O-linked), or 
asparagine (N-linked) residues [5]. Glycans can also be attached to lipids, such as the 
glycosphingosine, ceramide [6].  Unlike other protein modifications such as 
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phosphorylation, acetylation, or methylation, glycosylation poses a challenge to analysis 
due to extensive variation in glycan monomer composition, linkage between monomers, 
and overall placement. Further adding to the difficulty in studying glycan structure and 
function it should be noted that, unlike nucleic acids and proteins, glycans are not linked 
back to the genome, but result  from the numerous and coordinated actions of highly 
specific glycosyltransferases that can change  based on numerous localized conditions 
[7]. These events result in highly variable solutions of glycoforms, made of very slight 
alterations in the actual glycan structure. 
4.1.2 MCF-7
 Protein glycosylation is one of the primary post-translational modifications, and 
results in extensive biological implications. Changes in the glycosylation of proteins has 
been shown to change as a result of malignant transformation, making glycosylation 
alteration a common feature of disease such as cancer [8]. MCF-7, which stands for 
Michigan Cancer Foundation Line 7, was established in Detroit in 1973, and is the most 
commonly used breast cancer cell line in the world [9]. As of 2003, this line has been 
cited in literature more than 5 700 times [10]. As this line is well-documented, it is 
frequently used as a model line to characterize advances in instrumentation in 
methodology in proteomic studies. Because glycosylation has such a profound effect on 
cellular biology, monitoring of cellular glycosylation is vital in in-vitro cellular studies. 
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4.1.3 Therapeutical Biologics and Antibodies  
 Total revenues of antibody-based therapeutics generated about 20 billion USD in 
2007 [11]. Sale growth forecasts for antibody  therapeutics are 14% (vs 0.6% for small 
molecule- based therapeutics). Antibody-based therapeutics have a relatively  high success 
rate from clinical to the licensure (25-29% for antibodies vs only 11% for small-molecule 
drugs) [12]  It was reported by Reichert  in 2008 that a total of 205 mAbs were in clinical 
trials. It  was also estimated that from 1988 to 2006, 17% of all humanized mAb 
candidates that reached clinical trials were eventually approved by the FDA (as opposed 
to only 11% of small molecule drugs) [13].
 Biosimilar antibodies are “generic” (it  is important to use the term “generic” 
cautiously because generic versions of off-patent small-molecule drugs are exact copies 
of the original drugs) versions of an original drug, that contain the same amino acid 
sequence but are produced from different clones and manufacturing processes. These 
molecules may have different glycosylation patterns as well as other micro-variants that 
may  affect quality, safety, and potency. Bio-better antibodies target the same validated 
epitope but have been engineered to have improved properties. One of the most popular 
methods to do this is through changes in the glycosylation. [12]
4.1.4 Antibody Structure and the Effects of glycosylation
 IgG antibodies are comprised of two heavy and two light chains held together by 
covalent and non-covalent bonds to form three independent protein moieties connected at 
a flexible linker known as the hinge region (Figure 4-1).  The two Fab fragments serve as 
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the antigen-binding regions of the antibody, while the third Fc fragment, along with the 
site of glycosylation, at  asparagine at position 297, plays a major role in the 
communication and interaction with the immune system and cell surfaces [14]. The 
glycan is attached to the amino acid prior to the secondary, tertiary, and quaternary 
structure is formed, and is a major factor in the overall structure of the protein. Following 
the folding steps of the antibody, the glycan undergoes a number of glycan trimming and 
addition steps[15] . The basic structure of this N-linked glycan is that of a core structure 
comprising N-acetylglucosamine and mannose, with a variable region at the ends [16]. 
The type of glycosylation from IgG antibodies can vary  widely; although there is very 
little sialyation (<10%), antibody heterogeneity can result  in a potential of up to 128 
different glycoforms [17]. Utility of the the antibody as a therapeutic is through several 
possible functions. The primary  function is the use of the antigen binding regions to bind 
a specific target, halting the pathway that it  would be involved with. However, a number 
of other effects of antibodies are being engineered, including extensions of biological 
half-life and effector functions, such as antibody-dependent cell-mediated cytotoxicity 
(ADCC). Extending an antibody’s half-life provides a number of benefits, including an 
improved bioavailability and reduced amount or frequency of dosing [14]. These methods 
may be used to improve the efficacy of the drug or   decrease the cost of treatment to the 
patient. Many  biotherapeutics utilize effector functions such as antibody  dependent cell-
mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) as a major 
part of the drugs mechanism in the body. These modes of targeting cells for active lysing 
by the immune system is a potent method therapy for a number of diseases. When this 
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method of alteration is considered; however, the antibody is often engineered to shorten 
the biological half-life, so that patient does not suffer from undue  toxicity [14]. Current 
efforts are underway to enhance these effects by engineering the glycan structure. 
Methods to alter antibody glycosylation include changes in the cell culture production 
such as the choice of cell line, nutrient availability, amount of dissolved oxygen or 
ammonia, pH, culture viability, growth phase, and temperature [15]. Host cell lines, such 
as Chinese hamster ovary (CHO) have been selected to express antibodies with altered 
glycosylation such as increased amounts of bisecting N-acetylglucosamine or reduced 
amounts of fucose which serves to increase ADCC activity [18]. It is therefore necessary 
for both the manufacturer, as well as regulatory agencies, to profile and monitor the 
structural characteristics of these glycans. 
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Figure 4-1 Figure 4-1 shows a general depiction of a whole IgG antibody and a general 
depiction of the glycosylation found N-linked to  asparagine at position 297.
4.1.5 Trastuzumab (Herceptin)
 The human epidermal growth factor receptor family of of four receptors (HER1, 
HER2, HER3, and HER4, also known as ErbB) are tyrosine kinase receptors that 
normally regulate cell growth and survival. These receptors have an extracellular domain 
for ligand binding, a transmembrane segment, and with the exception of HER3, an 
intracellular tyrosine kinase domain [19]. The extracellular domain of HER2 is unique in 
this family because unlike the other three HER receptors, HER2 can adopt a 
conformation that permits dimerization when there is a lack of ligand [20]. This binding 
activates signal-transduction cascades of these receptors that promote cellular 
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proliferation, survival, as well as mobility and invasiveness [21]. The over expression of 
HER2 has been observed in the 20 to 30 % of breast cancer that has been classified as the 
most aggressive and with the worst prognosis. [22,23]. 
 Trastuzumab (Herceptin ®) is a recombinant monoclonal humanized IgG 
antibody that contains two antigen-binding sites specific to the extracellular domain of 
the HER2 receptor, effectively  blocking the receptor for ligand binding or dimerization. 
This prevents activation of the intracellular tyrosine kinase, and the cascade of events 
resulting in unchecked cellular growth [24]. Trastuzumab was produced by Genentech 
and was approved for the treatment of patients with HER2 over expressed metastatic 
breast cancer by the Food and Drug Administration (FDA) in 1998. Trastuzumab has 
been shown effective when used in conjunction with standard chemotherapy, and has 
been shown to extend the time to disease’s progression, increase response rates, and 
result in a longer median survival rate [25].  Trastuzumab is rarely  prescribed as a stand-
alone treatment, and is beneficial for  only  a small percentage of patients (only 
approximately 20%) when it is not combined with a secondary treatment such as cis-
platin chemotherapy [26]. As possible mechanisms of resistance are being investigated 
[27] a number of alternative therapeutics focusing on the same targets have been 
developed. Trastuzumab’s effectiveness has been shown to improve with the removal of 
fucose from the existing glycan structure. Removal of fucose has been shown to greatly 
enhance ADCC, and thus the effectiveness of the drug to target cancerous cells. A 
recently  study showed that defucosylated trastuzumab doubled the survival time in 
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comparison to fucosylated trastuzumab in preclinical models of HER2 overexpressed 
breast cancer [28]. 
4.1.6 Quality by Testing vs Quality by Design 
 The historical approach toward the approval of pharmaceutical products involved 
the identification of the process parameters  at each stage of development that have 
critical influence on product quality, then testing the end product to validate the process. 
This process, known as Quality by Testing has a number of important disadvantages, 
including the fact that any change in the manufacturing process requires validation, 
discouraging companies from changes, improvements, or optimization of the 
manufacturing process. The major regulation bodies in the United States and Europe 
(USFDA and EMEA) now encourage the incorporation of Quality by Design into the 
production pipeline. Quality  by  Design involves the understanding and utilization of in-
depth knowledge of the product and mechanisms at every of production. Quality by 
Design  concepts include a definition of the desired performances (clinical or in vivo), 
identification of critical quality attributes and the process parameters that affect these 
attributes, and sets of analyses during processing for the dynamic control of 
manufacturing to ensure that the defined product performances are achieved [29]. 
Because glycosylation is responsible for the considerable variability of mAb products, 
rapid, efficient analyses of glycosylation is vital to this industry.
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4.2 Experimental
4.2.1 Chemicals and Materials:
 Reagents were obtained from a variety  of manufacturers. Sigma Aldrich (St. 
Louis, MO, USA) was the source for asialofetuin from fetal calf serum, 3-(N-
morpholino)-propanesulfonic acid (MOPS), calcium chloride dihydrate, sodium chloride, 
maltooligosaccharide standards and sodium hydroxide. Methanol and α1-acid 
glycoprotein (AGP) were purchased from EMD Biosciences (La Jolla, CA). Ethanol was 
obtained from AAPER Alcohol (Shelbyville, KY). 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) and 1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC) were 
obtained from Avanti Polar Lipids (Alabaster, AL). 1-aminopyrene-3,6,8-trisulfonic acid 
(APTS) was purchased from Biotium (Hayward, CA). Sodium cyanoborohydride 
(NaCNBH3) was acquired from Strem Chemicals (Newburyport, MA). Triethylamine, 
acetonitrile, and citric acid were acquired from Fisher Scientific (Pittsburgh, PA). Fetal 
bovine serum was obtained from Thermo Scientific (Rockford, IL). Trastuzumab was 
obtained from Genentech (San Francisco, CA, USA). Ribonuclease B (Rnase B), α1-2,3 
mannosidase, β1-4 galactosidase, neuraminiase, β-N-Acetylglucosaminidase, and a 
peptide N-glycosidase (PNGase F) kit, were obtained from New England Biolabs 
(Ipswich, MA). A G7 10X reaction solution composed of 0.5M sodium phosphate 
buffered at pH 7.5, a glycoprotein denaturing solution containing 5% sodium dodecyl 
sulfate (SDS), and 0.4 dithriothreitol (DTT), and 10% solution of nonionic surfactant 
NP-40 were included in the PNGase F kit. A G1 10X reaction solution composed of 0.5M 
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sodium citrate buffered at pH 6 was provided in the neuraminidase kit. An Elga Purelab 
ultra water system (Lowell, MA) was used to provide deionized water. 
4.2.2 Culture of MCF7 Cells and Protein Isolations
 MCF7 cells (ATCC, Manassas, VA) were cultured by David Lowrey and Linda 
Sargent at the National Institute for Occupational Safety and Health (Morgantown, WV). 
Cells were cultured with Dulbecco’s Modified Eagle Medium (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum. The total protein was isolated from 
approximately 10 x 106 MCF7 cells in a T75 flask. Two mg/mL of total protein was 
isolated when the cells were approximately 70% confluent. The protein was extracted in 
50mM Tris-HCl, 1% Triton, 1.5 mM  MgCl2, 150 mM NaCl, and protease inhibitors. An 
83µg sample of the isolated protein fraction taken from the MCF7 cells was labeled with 
APTS as described.
4.2.3 Preparation and Derivatization of Glycans from MCF7 and Trastazumab
 Glycans derived from glycoproteins (Branched glycan standards, glycans from 
MCF7, and glycans from Trastuzumab) were prepared as follows. Glycans were removed 
from protein sources using a PNGase F kit using a protocol based on the kit  from the 
manufacturer. Briefly the protein is denatured using a solution containing SDS and DTT 
and heating at 95℃ for 10 minutes. The nonionic surfactant NP-40 is then added to the 
solution to prevent the DTT from denaturing the enzyme PNGase F, which immediately 
added afterward. This reaction was incubated at 37 ℃ overnight, rather than the 2 hours 
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suggested by the protocol. The next day, a 3X volume of ice-cold ethanol was added to 
precipitate the protein. The solution was centrifuged at 4℃ at  10 000 rpm for 10 minutes. 
The liquid fraction containing cleaved glycans was dried using a Savant SpeedVac 
concentrator (ThermoScientific, Waltham, MA). The dried glycans were reconstituted in 
1 µL  of a 0.2 M  solution of APTS dissolved in 1.2 M citric acid, along with 1 µL of 1 M 
NaCNBH3 in deionized water. The solution was thoroughly  mixed before being incubated 
overnight at 37 ℃. 100 µL of deionized water was used to stop the reaction. If needed, 
the sialic acid was removed by adjusting the pH of the glycan solution to 6 with sodium 
hydroxide then incubating it  overnight with neuraminidase. If necessary, a 10 kDa 
molecular weight cut off filter (Sartiorius, Stonehouse, UK) was used to remove the 
neuraminidase followed by removal of excess APTS by a Discovery DPA-6S solid phase 
extraction cartridge (50 mg packing, Supelco, Bellefonte, PA). A flush of 95:5 (v/v) 
acetonitrile:water was used to prepare the cartridge prior to use. APTS was eluted from 
the extraction cartridge with a solution containing 95:5 (v/v) acetonitrile:water containing 
50 mM trimethylamine. An aqueous solution of 50 mM triethylamine was used to elute 
the retained glycans from the cartridge. The glycan solution was evaporated to dryness 
and the reconstituted in 100 µL deionized water and stored at -20 ℃. Following labeling 
of the MCF7 glycans with APTS, a 1kDa molecular weight cutoff filter (MWCO) was 
used to remove APTS labeled- small molecules, such as monosaccharides. Prior to 
deglycoyslation and labeling of Trastuzumab, a 10 kDa MWCO filter was used to remove 
trehalose and other stabilizes from the protein antibody. 
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4.2.4 Preparation of Phospholipid Additive
 Preparations of phospholipids were comprised of 5 %, [DMPC]/[DHPC] (q value) 
= 0.5 were used for coating of the capillary, which serves to suppress the electroosmotic 
flow, and to passivate the surface from nonspecific interactions. Another phospholipid 
preparation of a 10 %,  q = 2.5, phospholipid solution was used for the separation media, 
due to it’s thermally-switchable gel-like viscosity. These phospholipids were prepared by 
weighing out the appropriate masses of dry DMPC and DHPC, then adding 100 mM 
aqueous MOPS buffered to pH 7. After the solution was thoroughly mixed, the 
preparation was subjected to a minimum of three freeze-thaw cycles and centrifuged for 
10,000 rpm for ten minutes. The phospholipid preparation was stored at -20 ℃, and was 
thawed and vacuum degassed prior to use. 
4.2.5 Capillary Electrophoresis
 Separations were performed using a P/ACE MDQ Capillary electrophoresis 
system (Beckman Coulter, Fullerton, CA, USA) equipped with laser induced 
fluorescence detection (air cooled argon ion laser, λex = 488 nm, λem = 520 nm). The 
fused silica separation capillary  had a 25 µm internal diameter and a 360 µm outer 
diameter (Polymicro Technologies, Phoenix, AZ, USA) with an effective length of 50.0 
cm and a total length of 60.2 cm. Capillaries were subject to the following flushing 
sequence daily: 1 M NaOH for 30 minutes at 170 kPa (25 psi), deionized water for 15 
minutes at  170 kPa (25 psi), methanol for 15 minutes at 170 kPa (25 psi), and 15 minutes 
of water at 170 kPa (25 psi). Following this flushing sequence, the capillary  was 
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passivated with a phospholipid coating with a 5 %, q = 0.5 phospholipid preparation 
containing 1.25mM  calcium. This semi-permanent coating was applied for 20 minutes at 
170 kPa (25 psi) followed by a 2 minute MOPS flush at 170 kPa (25 psi) to remove 
excess phospholipid and  from the capillary. A brief pre-coat was applied prior to each 
run using the following protocol at 170 kPa (25 psi) with the capillary  held at 19℃: q = 
0.5, 5% phospholipids for 3 minutes, MOPS for 2 minutes, and q = 2.5, 10% 
phospholipids for 3 minutes. If enzyme was being used in-capillary, an additional 3 
minute 170 kPa (25 psi) MOPS flush was performed in the reverse direction before this 
sequence, to expel any  enzymes from the capillary, and to prevent fouling of the capillary. 
When the room temperature was higher than 22 ℃, a portable air conditioner was used to 
provide ambient thermal control. Injections into the capillary  were carried out in three 
steps. First, a plug a MOPS was injected into the phospholipid filled capillary (7 sec, at 
6.9 kPa) at 19 ℃. The capillary temperature was then heated to 25 ℃, resulting in the 
viscosity  of the q = 2.5 10 % phospholipid filling to increase to a gel-like consistency. 
The glycan is then electrokinetically injected into the capillary. Finally  a post-plug of 
MOPS was pressure injected (5 sec, 3 kPa). Separations were carried out at 400 V/cm 
under reversed polarity. Data collection and analysis were performed using 32 Karat 
Software version 5.0 (Beckman Coulter). 
4.3 Results and Discussion
 Chapter 3 discussed how glycan-specific lectins and enzymes may be used to 
analyze solutions of glycans for structural characterization. In this chapter, these methods 
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of analysis are used on two different biological samples, demonstrating two different 
types of analyses. 
 In-capillary interactions may be used to probe and simplify highly complex 
samples of unknown glycans, such as those taken from the protein fraction of cellular 
samples. N-linked glycans from the immortalized human breast carcinoma cell line 
MCF7 were analyzed with capillary  electrophoresis. This highly complex sample was 
probed with lectins and enzymes to discern the overall characteristics, providing an 
analysis method that can be used monitor changes in the overall glycan composition. 
These changes may act as biological “clues” to reveal changes that are relevant to cancer. 
This method was also used on glycans with the uncharacterized low abundance glycans 
from the therapeutic antibody Trastuzumab, to discern the amount of glycans containing 
sialic acid. 
 The incorporation of enzymes into capillary may also be used to target and 
determine the sequence of specific glycans. Various exoglycosidase enzymes are used in 
combination to systematically  cleave terminal residues, revealing the sequence of the 
overall glycan structure. This method provides a rapid, low-tech method of determining 
sequence without the use of sophisticated instrumentation, such as mass spectrometry. 
This method is used to sequence the major isoform glycans taken from the therapeutic 
antibody Trastuzumab.
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4.3.1 Separation of Glycans from MCF7 Cells and Identification with Glycan 
Standards
 Glycans from the immortalized breast cancer cell line,  MCF7, were labeled with 
APTS and separated using phospholipid-assisted capillary  electrophoresis. The use of 
phospholipid additives as an easily incorporated, gel-like separations media provides 
superior separations efficiencies. These glycans were separated with efficiencies as high 
as 640 000 theoretical plates. The excellent separations efficiencies as a result of the 
phospholipid materials allow for superior resolutions  of high abundance glycans, as well 
as the detection and separations of low abundance glycans, as seen in Figures 2 and 3. 
Two of the low abundance peaks (as seen in Figure 3) were identified with the glycan 
standards mannose 5 and mannose 6. 
4.3.2 Analysis of MCF7 with Concanavalin A 
 Phospholipids provide excellent media for the incorporation of proteins such as 
lectins and enzymes. Because phospholipids are naturally the components of cellular 
membranes, phospholipids are inherently biocompatable and do not result in 
denaturation. Alternative methods of protein incorporation for analysis usually involve a 
method of conjugation such as biotin-streptavidin or covalent modification of the protein, 
which can result in denaturation of the protein and/or modification of the binding or 
reaction pockets of the protein. These may reduce subsequent protein binding or 
enzymatic activity. The methods of conjugation often utilize buffers, ionic strengths, and 
pHs that  can further damage the enzyme, and require lengthy cleanup steps prior to 
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utilization. In contrast, using the temperature-dependent viscosity of the phospholipid to 
immobilize the enzyme within the capillary  is achieved without modifications to the 
protein or phospholipid. 
 The lectin concanavalin A was used to reduce the complexity of the 
electropherogram of glycans taken from MCF7 cells. Analyses with off- or on-line of 
incubations of concanavalin A select for mannose-rich glycans that bind with high 
specificity, especially to glycans such as mannose 5 and mannose 6. The 
electropherogram shown below displays the major and minor glycans from MCF7. 
Glycans that responded to concanavalin A and thus had these structural characteristics are 
shown. The coefficient of variation of peak area was less than 10 %. Therefore the 
criterion for peaks that responded to enzyme or lectin was chosen to be 15 %. Any peak 
that responded by more than 15% was denoted in Figures 4-2 and 4-3. Mannose 
composition of the MCF7 glycans were primarily identified from using an off-line 
incubation with concanavalin A. These experiments showed that the majority  of glycans 
taken from the MCF7 cell line are structurally high in mannose, a characteristic that is 
supported in other literature sources [29]. The analyte peak identified as mannose 5 by 
glycan standards did not respond to concanavalin A. This may  be because of the low 
abundance of this peak and competing higher affinity  of other mannose-rich species. 
Additionally  others have reported that lectins may  display unusual interactions that do not 
obey predicted epitope binding [30].
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Figure 4-2 is the electropherogram of the labeled glycan fraction derived from MCF7 
cells. Glycan composition is interrogated using the enzymes β1-4 galactosidase, α1-2,3 
mannosidase, or the lectin concanavalin A.This figure was reproduced with permission 
from [2]. Copyright 2011 American Chemical Society.
4.3.3 Analysis of MCF7 with galactosidase, mannosidase 
 The enzymes α1-2,3 mannosidase and β1-4 galactosidase were used for in-
capillary interactions with the MCF7 glycans. The enzyme α1-2,3 mannosidase cleaves 
terminal α1-2 or α1-3 mannose residues and can be used along with the lectin 
concanavalin A to confirm the characteristics of a high-mannose glycan. The enzyme 
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β1-4 galactosidase selectively  cleaves terminal β1-4 galactose residues and is an indicator 
of branched glycan species. 
Figure X
Time (min)
1918 2016 22 23 25 26
0.01 RFU
Man6
Man5
17 21 24 2715
! !!!
!
!
!
!
!
!! !
! ! ! !
!
Figure X is the electropherogram of the labeled glycan fraction derived from MCF7 cells 
with the figure size blown up to show  the low  abundance peaks. Glycan composition is 
probed with the enzymes !1-4 galactosidase, "1-2,3 mannosidase, or the lectin 
concanavalin A.  
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Figure 4-3 is the electropherogram of the labeled glycan fraction derived from MCF7 
cells with the figure size blown up to show  the low  abundance peaks. Glycan 
composition is probed with the enzymes β1-4 galactosidase, α1-2,3 mannosidase, or 
the lectin concanavalin A. This figure was reproduced with permission from [2]. 
Copyright 2011 American Chemical Society.
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4.3.4 Identification of the major glycans from Trastuzumab  
 Glycosylation of the humanized immunoglobulin IgG1, Trastuzumab is primarily 
fucosylated N-linked biantennary complex glycans [17,31]. The major glycans from 
Trastuzumab are shown in Figure 4-4. These glycans have been confirmed through a 
number of literature sources and comprise 99% of the major glycans from the antibody. 
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Figure 4-4 displays the highest abundance structures characterized for Trastuzumab 
(Herceptin ®), as well as the naming used for this study. 
4.3.5 Separations of glycans from Trastuzumab  
 Glycans from Trastuzumab were labeled with APTS and separated using 
conditions previously reported. The results are shown in Figure 4-5. A 60.2 cm, 25 µm 
inner diameter capillary was coated with Q 0.5 5 % phospholipid, rinsed with MOPS, 
then filled with Q2.5 10 % phospholipid.  Glycans were injected, then separated using a 
field strength of 400 V/cm. The major abundance glycans from Trastuzumab had 
separation efficiencies ranging from 410,000 plates (G0F) to 510, 000 plates (G2F). The 
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identities of these glycans were determined based on migration order and abundance 
based on characterization by CE and other methods in the literature. Other reported 
methods utilizing capillary electrophoresis utilize linear polyacrylamide gel separation 
media [31] and the same APTS tagging methods used in this study. However the 
efficiencies of separation were only an estimated 65,000 (value based on hand 
calculations from figures) compared to our 510,000. An additional benefit  of the 
phospholipid separations media is that the low abundance glycans, which make up ~1 % 
of the total glycan can be efficiently resolved and detected. These glycans, which are not 
well-characterized in literature, are shown in Figure 4-5-B.  Three of these low-
abundance glycans were identified as high mannose structures (mannose 5 and mannose 
6) as well a a branched dianntennary  structure (AI). Although the use of glycan standards 
can be utilized to confirm structural identity  of glycans from a sample, the high cost and 
limited commercial availability  prevent this method from being truly  viable, especially 
for users with limited resources.  
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Figure 4-5 is the electropherogram of the labeled glycan fraction derived from 
Trastuzumab. The highest abundance glycans G0, G2F, G1F, G1F’, and G0F are 
labeled based on literature characterization of glycosylation. The identities of three of 
the lower abundance peaks are confirmed using glycan standards (mannose 5, 
mannose 6, and the branched diantennary A1). The peak labeled with an * is an 
internal standard. Peak efficiencies were as high as 510,000 peaks for G2F. 
Reproduced with permission from [4].
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4.3.6 Characterization of sialyated glycans from Trastuzumab
  The determination of the amounts of sialic acid (N-Acetylneuraminic acid) is 
beneficial to biotherapuetic monitoring and production. Although sialic acids constitute 
<10% of glycans derived from IgG antibody, they are nonetheless a valuable constituent. 
Terminal sialic acid has been found to increase the circulating half-life of a biotherapeutic 
drug, and thus its efficacy [30].   Sialic acids pose difficulty for analysis because, unlike 
other glycan residues, they  each provide a minus one charge, altering the expected 
migration time. They are also thermally labile and hydrolyze at  low pH, which poses a 
challenge to analysis with mass spectrometry. Sialic acids are commonly  removed from 
glycans prior to analysis with the enzyme neuraminidase, which is fast-acting and 
commercially available through a number of sources. To probe the solution of glycans 
taken from Trastuzumab, a small plug of neuraminidase in pH 5.0 citrate buffer was 
injected into the capillary  (1.5psi 15 sec). The glycan was injected into the capillary, 
electrokinetically moved onto the enzyme plug and was subjected to a 5 minute 
incubation time, then separation through the capillary. The resulting electropherograms 
are shown in Figure 4-6-B, which is an expanded view of the low abundance glycans. 
The solid trace is of a separation following incubation for 5 minutes in a blank containing 
only pH 5 citrate buffer. The dashed trace is following incubation for 5 minutes in a plug 
containing the Neuraminidase enzyme. The four low-abundance glycans from 
Trastuzumab that are denoted in Figure 6 responded to the enzyme. As can be seen in 
Figure 4-6-B, which is a full-scale view of the same electropherograms, these glycans 
constitute only a minor portion of the total glycan composition. Based on this study and 
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following comparison of the glycan areas, only ~1% of the total glycan content of 
Trastuzumab is sialyated. 
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Figure 4-6 is the electropherogram demonstrates the use of the enzyme 
Neuraminidase for probing low abundance sialated glycans from Trastuzumab. The low  
abundance glycans that responded to Neuraminidase are denoted in Figure 6-A and 
shown in Figure 6-B. Glycans were incubated with an in-capillary plug of 
Neuraminidase for 5 minutes prior to separation and analysis with CE-LIF. Reproduced 
with permission from [4].
4.3.7 Analysis with multiple in-capillary enzymes
To determine the complete glycan structure the sample can be treated sequentially with 
multiple enzymes. Figure 4-7 and 4-8 show how two enzymes can be incorporated into 
the capillary through multiple incubation and separations steps. In figure 4-7-A, the 
glycan sample is injected into and incubated within a capillary  containing only blanks 
and no enzymes. The glycan is unaffected by these blanks and separated in the capillary 
at the expected migration time. In figure 4-7-B, an enzyme that cleaves the terminal 
outer-most glycans is introduced into the capillary. The glycan is injected into the 
capillary and incubated, resulting in the enzymatic cleavage of that glycan residue. As a 
result, the electrophoretic mobility of this glycan has changed, and now during separation 
the glycan will have a different migration time. This process is continued in Figure 4-7-C 
where two enzymes are injected, the second enzyme specific for the next level of glycans. 
The glycan is injected, moved to the first enzyme plug and incubated, then moved to the 
next enzyme plug and incubated. Two levels of glycan residues are removed, and the 
glycan is then separated with a third migration time. During this process three different 
experimental separations following incubation are conducted. Because the identification 
of the glycan is dependent on migration time, it  is critical that all methods utilize the 
same injection/incubation/transfer protocol. 
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Figure X demonstrates how multiple enzyme plugs can be used to probe the glycan for 
sequential data. A glycan of interest is first separated in a capillary containing no enzyme 
(Figure X-A). The glycan is then separated through a capillary containing a single enzyme 
to remove the terminal glycan residues, in this case the terminal !1-4 galactose resides 
(Figure X-B). The glycan is then separated in a capillary containing two enzymes to remove 
two sequential layers of glycans, first the galactose residues, then the glucosamine 
residues (Figure X-C). 
Figure X
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Figure 4-7 demonstrates how multiple enzyme plugs can be used to probe the glycan 
for sequential data. A glycan of interest is first separated in a capillary containing no 
enzyme (Figure 7-A). The glycan is then separated through a capillary containing a 
single enzyme to remove the terminal glycan r sidues, in this case the terminal β1-4 
galactose resides (Figure 7-B). The glycan is then separated in a capillary containing 
two enzymes to remove two sequential layers of glycans, first the galactose residues, 
then the glucosamine residues (Figure 7-C). 
4.3.8 Use of multiple enzyme plugs to Characterize Major Glycans from 
Trastuzumab 
 The enzymes used to characterize glycans from Trastuzumab were β1-4 
galactosidase and β-N-Acetylglucosaminidase. A general schematic of the enzymes 
placement in the capillary is seen in Figure 8. MOPS plugs placed between the enzyme 
plugs and after the second plug, were used to prevent carryover between the enzyme 
vials, and contamination of the glycan sample. The Trastuzumab glycans were injected 
into the capillary, moved electrokinetically onto the first enzyme plug (10 kV 30 sec), 
incubated for 10 minutes, moved to the second plug (10 kV 30 sec), then incubated for 
another 10 minutes and separated. Figure 4-8 shows a blank reaction where both 
incubations took place in pH 5 Citrate buffer plugs. The separation efficiency  for G0F 
was ~100,000 plates (vs 410,000) in spite of longitudinal diffusion due to the 20 minute 
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total incubation time and because of the electrokinetic movement steps. When the 
reactions took place with enzymes, the plate count decreased to ~35,000 following due 
specific and nonspecific interactions with the protein. 
 When the glycan is subjected to only β1-4 galactosidase, it  demonstrates that 
three of the four major glycans from Trastuzumab (G1F, G1F´, and G2F) contain β1-4 
terminally linked Gal residues, as shown in Figure 4-9-B. This experiment can also be 
repeated with only  β-N-Acetylglucosaminidase, to see if there are terminal GlcNAc 
resides (shown in Figure 4-9-C). In this experiment the peaks affected include (G0F, G1F, 
and G1F´). Because there are no exposed GlcNAc resides in G2F, this peak was 
unaffected by the enzyme. Treatment with both enzymes, as shown in Figure 4-9-D, show 
that all four peaks are reacted. If this reaction is continued, it will complete cleavage 
d o w n t o a f u c o s y l a t e d m a n n o s e c o r e .
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Figure X demonstrates the use of multiple in-capillary plugs of enzymes to analyze glycans 
from Herceptin. Small discrete plugs of enzymes may be injected into the capillary prior to 
introduction of the glycan. The glycan is injected, then moved onto each plug before 
incubation. Once the glycan has been incubated in each of the plugs it is separated and 
detected using CE-LIF. 
Friday, August 5, 2011
Figure 4-8 demonstrates the use of multiple in-capillary plugs of enzymes to analyze 
glycans from Herceptin. Small discrete plugs of enzymes may be injected into the 
capillary prior to introduction of the glycan. The glycan is inject d, then moved onto 
each plug before incubation. Once the glycan has been incubated in each of the plugs 
it is separated and detected using CE-LIF. Reproduced with permission from [4].
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Figure 9 demonstrates the injection plug strategy described in Figure X, using the enzymes 
!1-4 galactosidase and  !-N-acetylglucosaminidase, either singly (Figures 9-B and 9-C) or 
sequentially (Figure 9-D)
Wednesday, October 12, 2011
Figure 4-9 demonstrates the injection plug strategy described in Figure 8, using the 
enzymes β1-4 galactosidase and  β-N-acetylglucosaminidase, either singly (Figures 9-B and 9-
C) or sequentially (Figure 9-D). Reproduced with permission from [4].
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 This set of experiments can be expanded to include a number of other enzymes. 
Because sialic acid is in such a low abundance in Trastuzumab, it was not necessary  to 
include the enzyme neuraminidase to the enzyme regimen. However, because this 
enzyme is fast-acting, having incubation times of roughly  5 minutes, it is simple to add 
neuraminidase into a three-enzyme  set of analyses. It is important to note that the 
optimum pH for all exoglycosidases is similar (~pH 4.5 to pH 6). This means that, rather 
than individual plugs of enzyme within the capillary, various enzymes may be combined 
in cocktails for a single plug/ multiple reaction system. This method may provide 
improved plate counts, as the number of incubation and move steps have decreased. 
However, because this approach utilizes more total enzyme and total liquid handling, it 
was not tested.  
4.3.9 Benefits of Using In-Capillary Analysis for Multiple Enzyme Studies
 The benefits of utilizing this method include drastically reduced amounts of 
enzyme and sample, as well as time, as documented in Chapter 3. To emphasize the 
benefits of in-capillary reactions specifically  for multiple enzymes, a comparison to an 
equivalent bench-top  analysis must be made. In this system a glycan solution is being 
probed with two enzyme solutions, and a limit of 20 µL volume size is required for 
injection by an automated CE system (Beckman P/ACE MDQ). Figure 10 shows the 
approaches that can be taken for multiple enzyme reactions, followed by  analysis, either 
serially (top figure) or in parallel (bottom figure). Serial bench top  reactions involve the 
full analysis of a sample, the enzymatic reaction of the entire sample followed analysis, 
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followed by the final enzymatic reaction and more analysis. This method conserves the 
total consumption of the glycan by using a single sample for multiple reactions but 
increases the total experiment time. Additionally, sufficient analyses must be completed 
before the next enzyme is used. Once an enzyme has been added to the glycan sample it 
cannot be reused for repeated analyses of the prior steps. In contrast, parallel bench top 
reactions utilize multiple samples or aliquots for multiple enzymatic reactions to incubate 
simultaneously. Thus parallel analyses have faster experiment times, and samples that can 
be reused, but consume significant amounts of glycan sample. It is also important to note 
that the addition of enzyme in both parallel and series analyses affects both the glycan 
concentration and the injection into the capillary. In contrast to these methods, utilizing 
enzyme plugs in the capillary for on-line analyses utilizes a single glycan sample for 
multiple, repeatable analyses. In-capillary  sequencing uses ~2 nL of enzyme and 1 nL of 
glycan per injection, allowing for numerous reactions to be completed without 
compromising the original sample, making this method especially  useful for volume 
limited glycan samples.
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Figure 4-10 demonstrates the various methods of bench-top enzymatic sequencing 
using multiple exoglycosidase enzymes 
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4.4 Conclusions 
The incorporation of exoglycosidase enzymes and lectins is an appealing strategy to 
probe complex solutions of glycans for structural characteristics. Phospholipid-assisted 
capillary electrophoresis provides a highly efficient separations (~500,000 theoretical 
plates) and utilizes small sample volumes in an automated method. The temperature-
responsive phospholipid separations material also provides a rapid, noncovalent method 
to incorporate enzymes directly  into the capillary. This method greatly reduces the 
amount of enzyme and sample. Additionally the sample may be utilized for multiple 
analyses. These methods were used to probe glycoprotein solutions of the immortalized 
MCF-7 breast cancer cell line, determining whether glycans were high-mannose glycans 
or had terminal mannose or galactose residues. Both high and low abundance glycans 
were analyzed using these methods. The therapeutic antibody, Trastuzumab (Herceptin®) 
was also analyzed using similar methods. The enzyme neuraminidase was used to 
identify low abundance sialyated glycans, even though these glycans make up less than 
1% of the total glycan content. The enzymes β1-4 galactosidase and β-N-
acetylglucosaminidase were used both individually  in different separations, and 
sequentially in a single separation to determine the structure of the main glycans of 
Trastuzumab. 
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4.5 Future Directions: 
Lectin Bind-and-Release using Phospholipid Assisted Capillary Electrophoresis: Glycan 
analysis using lectins held within phospholipid is a powerful way to quickly  probe 
diverse solutions of glycans for those with a specific set of characteristics. Glycans that 
have specificity  to the lectin within the capillary, bind to the lectin and are also held 
within the capillary, while the rest of the glycans continue to move through the capillary. 
This means a selection of glycans sharing a common characteristic (i.e. high mannose or 
branched mannose structures) can be retained for further analysis. If the plug of enzyme 
is flooded with a glycan solution that  disrupts the glycan binding and displaces these 
glycan, the previously bound glycans can be subsequently released and separated for 
further analysis, such as with CE-MS analysis. 
Analysis of O-linked glycans and glycosaminoglycans: All studies completed in this body 
of work centered on the analysis of N-linked glycosylation. However these are not the 
entirety  of glycans from protein sources. O-linked glycans attach via oxygen to serine and 
threonine and have a wide variety of structures.
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